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CHAPTER I
INTRODUCTION
Introduction
Over the last decade there has been an increasing interest in vascular 
stiffness, the loss of blood vessel wall elasticity in the major arteries, because it is a 
risk factor for cardiovascular events, especially stroke 38. Arterial compliance is 
defined as the ability of an artery to expand and recoil with cardiac pulsation and 
relaxation3. The human aorta gradually becomes stiffer with age, with the process 
of arteriosclerosis developing even if there are no other concurrent diseases79. The 
cardiovascular structure and function include thickening of the vessel wall, a 
decrease in systemic arterial compliance and cross-sectional distensibility of the 
large elastic arteries. These changes lead to an increased cardiovascular disease risk 
in elderly subjects42.
The increased prevalence of obesity in the United States has reached 
epidemic proportions, and is still increasing among all age-groups 29’82. Obesity 
may negatively affect cardiovascular function through associations with 
hypertension, dyslipidemia 129, and inflammation21,134. Increased stiffness of the 
arteries is often seen in patients with autoimmune or inflammatory disorders, in 
terms of increased concentrations of various inflammatory markers. The chronic 
state of raised inflammatory concentration can have detrimental effect on the 
vasculature. Over time, this can lead to decreased nitric oxide bioavailability, 
vascular wall damage and ultimately decrease the ability of the arteries to dilate, 
thereby increasing the propensity for an adverse cardiovascular event " .
1
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The early detection of atherosclerotic changes in the aorta may have a clinical 
significance for prediction of cardiovascular disease79. Arterial stiffness can be 
assessed noninvasively with the use of pulse contour analysis (PCA) measurements. 
This device can measure the velocity of the pulse wave to travel a given distance 
between two sites of the arterial system 10.
Physical exercise has shown to be beneficial for protection against 
atherosclerotic vascular damage in elderly male athletes compared to elderly 
sedentary males32, and to attenuate the age-related changes in arterial stiffness in 
elderly male athletes 43, which may reduce the risk of having a cardiovascular event 
69,12°. Habitual exercise has been associated with a decrease in arterial stiffness in 
women and these benefits were associated with lack of increase in systolic and 
arterial pulse pressures 101. Furthermore, King well et al. showed that aerobically 
trained middle-aged athletes had lower stiffness than their sedentary counterparts, 
and time to exhaustion on treadmill testing in older subjects correlated positively 
with arterial compliance48.
Conflicting findings have been reported for the effects of resistance training 
on arterial stiffness. Kingwell et al. demonstrated that a 30-min bout of moderate 
intensity cycling using both legs decreased Pulse Wave Velocity (PWV), which is 
an index of arterial stiffness 49. A low-intensity single-leg exercise intervention also 
yielded a significant decrease in PWV in the exercised leg, but not in the control 
leg, suggesting the decrease in stiffness was induced by some exercise-related 
localized factor 107. Both cross-sectional studies74 and intervention resistance
n r c
training studies have reported decreases in large artery elasticity in healthy men.
2
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Although exercise seems to have a beneficial effect on the vasculature, this effect is 
not maintained in the absence of exercise31, suggesting the importance of 
maintaining a physically active life to sustain a healthy vascular function.
Cardiovascular disease is an exponentially growing problem in our society. 
The seriousness of this problem will only continue to grow unless we can propose 
appropriate therapies and interventions to counteract this problem. Based on 
previous literature, it is evident that endurance-type exercise has beneficial effects 
on the vasculature, in terms of down-regulating and decreasing various risk factors 
associated with endothelial dysfunction, such as hypertension, diabetes, obesity, and 
inflammation. Resistance training has a profound effect on the musculoskeletal 
system, contributing to maintenance of muscle strength and bone health 45.
However, the effect of resistance training on the cardiovascular system is still 
unclear, with the majority of examinations completed only in men.
Purpose
The primary purpose of this study was to examine the effect of twelve weeks 
of resistance training on large (Cl) and small (C2) arterial elasticity in 
premenopausal healthy women, and in healthy controls. The secondary purpose 
was to examine the relationship between the inflammatory marker C-reactive 
protein (CRP), and arterial elasticity in premenopausal healthy women, and in 
healthy controls.
3
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Research Questions
1. Will twelve weeks of lower leg resistance training change arterial 
elasticity and levels of CRP in premenopausal women?
2. What is the relationship between CRP and arterial elasticity in 
premenopausal women?
Hypotheses
1. Twelve weeks of lower leg resistance training will change arterial 
elasticity.
2. It is expected that there will be a negative relationship between C- 
reactive protein concentrations and arterial elasticity measures.
Significance
The significance of this study was to provide greater insight into the effect of 
resistance training on various cardiovascular parameters, specifically arterial 
elasticity. Aerobic exercise has been shown to increase arterial elasticity 32,43,112,
115, whereas the effects of resistance training still remain controversial 74,75,95,107. 
Information collected in this study will help us gain insight into how the large and 
the small arteries are affected by resistance training, and whether it has an effect on 
the inflammatory marker C-reactive protein.
Most studies have focused on inflammatory markers and their association 
with whole body resistance training, mostly in men, and have not examined the 
various cardiovascular parameters in depth. To our knowledge, this is the first
4
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investigation to examine large and small arterial elasticity in adult women after 12 
weeks of lower leg resistance training.
Assumptions
1. All subjects gave maximum effort during 1-RM testing.
2. All subjects completed the recorded sets and repetitions.
3. All subjects answered the questionnaires truthfully.
4. All subjects fasted for at least eight hours prior to blood draws.
5. All subjects were both fasted and rested for at least eight hours prior to 
pulse contour analysis measurement.
6. The subjects cooperated with the researcher to maximize the validity of 
each measurement.
7. The researchers were experienced testers on the specific instruments that 
were used for this investigation.
Delimitations
1. This study included premenopausal women between the ages of eighteen 
and fifty years.
2. All subjects were free of any history of cardiovascular disease, coronary 
heart disease, peripheral arterial disease.
3. The subjects did not take antihypertensive drugs, hormone replacement 
therapy, or hormonal birth control.
4. The subjects participated in the resistance-training program for twelve 
weeks.
5
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5. The HDI/Pulsewave™CR-2000 Cardiovascular Profiling System 
(Hypertension Diagnostic, Inc., Eagan, Minnesota, USA) was used to 
measure arterial elasticity.
6. The subjects were recruited from the University of Oklahoma, Norman 
campus and the surrounding areas.
Limitations
1. Daily physical activity outside the training session was not controlled. 
However, subjects were asked to continue their normal daily activity that 
did not include resistance training.
2. Pulse Contour Analysis (PCA) is a noninvasive measurement that allows 
only an estimate of the distance traveled by the pulse. The most accurate 
measurement of this distance can be obtained only with invasive 
procedures.
Operational Definitions
1. Dual energy x-ray absorptiometry (DXA) -  Measures the attenuation of 
energy passing through bone, lean tissue, and fat. DXA is used to 
measure bone mineral density (BMD), bone mineral content (BMC), and
‘j ' i
soft tissue composition .
2. Arterial Stiffness -  The loss of blood vessel wall elasticity3S.
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3. Endothelial Dysfunction -  The functional and reversible alteration of 
endothelial cells, resulting from impairment of nitric oxide 
availability 28.
4. Large Artery (O ') -  Proximal vessel such as the aorta 91.
5. Small Artery (C2) -  Distal vessel such as the small arteries and 
arterioles 91.
6. Pulse Contour Analysis (PCA) -  Noninvasive method to assess vascular 
compliance 98. A modified Windkessel model is used to estimate the 
large and the small arterial elasticity, which also includes other 
cardiovascular parameters 2.
7. C-Reactive Protein ('CRP') - Inflammation blood marker that is 
predictive of atherosclerosis 130 and future cardiovascular events 70,134.
8. One Repetition Maximum (T-RM) -  The maximal amount of weight that 
can be lifted during one complete repetition89.
9. Muscular Strength -  Maximum force that can be generated by a muscle 
or muscle group89.
10. Premenopausal -  Women that have regular menstrual cycles that have 
not changed in length35.
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CHAPTER II
REVIEW OF THE LITERATURE 
Introduction
Cardiovascular disease (CVD) is the leading cause of death and disability in 
the developed world, and might soon overtake infectious diseases as the precursor 
of death worldwide 78. Atherosclerosis is an important contributor to this increased 
risk of CVD 10. It has been suggested that atherosclerosis is a progressive disease 
originating from a combination of endothelial dysfunction and damage, thrombosis 
and inflammation U1.
Endothelial dysfunction is often seen in patients with inflammatory diseases 
in terms of increased concentrations of inflammatory markers, which over years can 
lead to vascular deterioration and reduced nitric oxide bioavailability. Such 
endothelial and vascular wall cell damage can impair the ability of the arteries to 
dilate, promoting increased stress and pressures on the vascular tree, and leading to 
potential detrimental cardiovascular events n . Other risk factors for increased 
stiffness of the arteries are adiposity 64’109,125, diabetes 15, hypertension 10’92, 
atherosclerosis 10, hypercholesterolemia m , and smoking6l. Inflammation is a 
potent vascular risk factor in the general population and is associated with 
endothelial dysfunction .
Elevated levels of concentration of inflammatory markers has been seen in 
autoimmune disease, such as multiple sclerosis 105, and rheumatoid arthritis 
(RA) 13°. Reduced arterial elasticity has been shown in RA patients with elevated
8
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levels of inflammatory markers130. Given the relationship of inflammation to 
atherosclerosis, elevated levels of inflammatory markers might be associated with 
decreased arterial elasticity. C-reactive protein (CRP) has been associated with
1 o  i
increased pulse wave velocity (PWV), hence stiffer arteries . Increased PWV or 
decreased pulse contour analysis (PCA) is associated with increased risk for
71cardiovascular disease and mortality rates .
The arteries become stiffer with advancing age 114, and these changes are 
related to various pathological states common to older individuals, such as 
hypertension 10,92, chronic heart failure uo, ischemic stroke 108, and future
71cardiovascular events, such as death .
Arterial elasticity can be assessed noninvasively using the HDI/Pulsewave™ 
CR-2000 Research Cardiovascular Profiling System (Hypertension Diagnostics, 
Inc.). This device consists of an oscillimetric blood pressure module, an Arterial 
Pulsewave™ Sensor Analyzer, and a computer system. The CR-2000 reads and 
analyses the blood pressure waveforms from the Arterial Pulsewave™ Sensor 
Analyzer. A profile report is generated, and includes systolic, diastolic, and mean 
arterial blood pressures, pulse pressure, pulse rate, estimated cardiac ejection time, 
estimated stroke volume and index, estimated cardiac output and index, large and 
small arterial elasticity indices, systemic vascular resistance, and total vascular 
impedance 91.
While the subject maintains a supine position on a therapy table, a blood 
pressure cuff is placed on the upper left arm, and a plastic rigid wrist stabilizer is 
placed on patient’s right wrist to minimize any movement and stabilize the radial
9
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artery during the 30-sec collection of blood pressure waveform. The Arterial 
Pulsewave™ Sensor Analyzer is placed on the surface of the skin right on the radial 
artery with just enough pressure without occluding the radial artery. This technique 
is reported to be a reliable 57 and a repeatable 91 index of aortic stiffness, 
independent on arm used for the analysis2.
This literature review will cover the pathophysiology of endothelial 
dysfunction, and explore the relationship of arterial elasticity with age, gender, 
hypertension, obesity, and inflammation. We will further examine the effect of 
various types of training on the vasculature, such as endurance training, resistance 
training, and finally a combination of endurance training and resistance training.
Pathophysiology of Endothelial Dysfunction
The endothelium is comprised of a thin cellular layer that lines the inner
surface of the blood vessels, separating the circulating blood from the tissues. The 
endothelium works as a receptor-effector organ and responds to various stimuli with 
the release of appropriate substances which help maintain tissue homeostasis. The 
endothelium thus modulates the vascular smooth muscle cells producing relaxation 
or contraction, and thereby vasodilation or vasoconstriction. Homeostasis of the 
endothelium is generated by controlling the production of various thrombotic 
components, such that it intervenes in cell proliferation and migration, regulates 
monocyte and leukocyte adhesion and activation, and the inflammatory processes.
Cardiovascular risk factors causes oxidative stress, or reduced nitric oxide 
bioavailability, that changes the capacity of endothelial cells to maintain a healthy 
vasculature, leading to endothelial dysfunction, and therefore reducing the capacity
10
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of the endothelium to maintain homeostasis. When endothelial cells lose their 
ability to maintain homeostasis, the tissue environment is right for the endothelium 
to be invaded by lipids and leukocytes. The inflammatory response is stimulated 
and fatty streaks appear, which is the first step in formation of atherosclerotic 
plaques. If the plaque build up persists and is exposed to rupture, this can set the 
stage for thrombogenesis and vascular occlusion24.
The functional impairment associated with a decrease in arterial elasticity is 
exacerbated by endothelial dysfunction, which is often associated with aging and 
hypertension. Endothelial dysfunction is characterized by impaired endothelium- 
dependent vasodilation33,113, due to a decreased nitric oxide production, which is 
due to an increased oxidative stress, which then leads to decreased nitric oxide 
synthase activity46,113.
The vessel wall alters its structure and function in response to direct injury 
and/or tensile and shear stress 34,77,133. The characteristics of arterial remodeling 
depend on the magnitude of stress the vessel is exposed to and on the presence of an 
intact endothelium 118,119. Blood flow is the primary determinant of arterial wall 
stretch and tensile stress. With increased blood pressure or arterial radius, tensile 
stress is maintained within physiological range by thickening of the vessel wall with 
retention of normal internal diameter. Changes in blood flow result in changes in 
shear stress within the blood vessel, which is responsible for the dragging frictional 
force. Experimental and clinical studies suggest that acute and chronic 
augmentation of arterial blood flow induce proportional increases in the vessel 
lumen, whereas decreasing blood flow reduces the arterial inner diameter 44,53.
11
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Age and Arterial Elasticity
Advancing age is associated with changes in the arterial structure and
function, such as thickening of the vessel w all86, and a reduced arterial compliance 
and distensibility of the large arteries 114. A decrease in arterial compliance or an 
increase in arterial stiffness commonly occurs with advancing age in both men and
no 101women , even in the absence of other concurrent diseases
The decrease in functional capacity of the cardiovascular system with 
advancing age is a repercussion of primary and secondary aging. Primary aging is 
due to progressive and age-related structural and functional deterioration in the 
cardiovascular system over time. Secondary aging, on the other hand, is attributed 
to hypertension, coronary artery disease, diabetes mellitus, and physical inactivity 
that stimulate the age-related decline in cardiovascular reserve capacity 14.
The decrease in arterial elasticity with advancing age is characterized by
r  1
arterial distension and increased arterial wall thickness . These structural changes 
are the result of intimal growth and changes in the middle layer of the artery, the 
media. There is a higher fibronectin content, increased collagen concentration 
stimulated by the release of growth factors, increased collagen cross-linking, 
decreased elastin, and smooth muscle cell proliferation, which result in increased 
media thickness and stiffness of the arteries6’51.
The age-related arterial changes that lead to decreased arterial elasticity are 
heterogeneous, being more pronounced in the aorta and central large, elastic-type, 
capacitative arteries than in the peripheral, muscular-type arteries 5.
12
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Gender Differences
There seem to be a gender difference in arterial stiffness, with women
having stiffer arteries than their male counterparts both before puberty 1 and after 
menopause 121. These results are attributed to hormonal differences, with women 
having a greater prevalence of systolic hypertension8. Distensibility or compliance 
of the large arteries is negatively affected by natural menopause in apparently 
healthy women , and hormone replacement therapy seems to attenuate arterial 
stiffness in postmenopausal women 73,76,93.
The underlying physiological mechanism by which menopause affects 
arterial elasticity remains unclear. It has been hypothesized that estrogen might 
change the structure of the arterial wall. In vitro examinations and animal studies 
have shown that estrogen decreases collagen production and the elastin/collagen 
ratio 91. Regardless of menopausal status, highly physically active women do not 
experience the age-related increases in central arterial stiffness as seen in sedentary 
women, emphasizing the importance of exercise 114. This study also showed that 
central, but not peripheral, arterial stiffness increases with advancing age in 
sedentary healthy females, which is in agreement with other examinations 115. 
Similarly, peripheral arterial elasticity is not different between sedentary and 
resistance trained individuals74. It has been suggested that the physiological 
mechanism behind the decrease in arterial elasticity with increasing age are more 
rapid in the large elastic arteries compared to the small muscular arteries 40. The 
large arteries have a cushioning function that damps fluctuations in flow, whereas 
the small arteries do not exhibit the same extent of pulsatile changes in diameter, 
and may not undergo the adaptations leading to decreased elasticity of the artery 13.
13
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Hypertension and Arterial Elasticity
The arterial remodeling and stiffness of the arterial wall that occur with
advancing age, induce systolic hypertension, pulse pressure, and a reduction in 
diastolic blood pressure6’51. Elevated arterial blood pressure is more prevalent with 
an increase in age , sedentary lifestyle , and a decrease in arterial elasticity . 
Several epidemiological studies have reported an inverse relationship between blood 
pressure and habitual physical activity either assessed by questionnaire or interview, 
or measured objectively 25.
Decreased arterial elasticity is associated with changes in blood pressure 
profile, such as isolated systolic hypertension and pulse pressure. Increased pulse 
pressure could be a result of increased systolic hypertension and or a decreased 
diastolic pressure which is common in advanced arteriosclerosis and is responsible 
for the diastolic pressure stabilization or decline that is often seen after the age of 60 
years . Systolic hypertension among the elderly can be considered an expression 
of advanced arterial stiffness, which is a major component of cardiovascular aging 6.
Arterial elasticity is “pressure-dependent” 63, and in hypertensive patients, 
the decrease in arterial elasticity is partially due to increased distending blood 
pressure rather than thickening of the arterial wall and changes in intrinsic 
biomaterial stiffness 5S. Systolic blood pressure and pulse pressure during maximal 
exercise has been shown to be associated with impaired endothelial vasodilator 
function in the brachial artery, independent of resting blood pressure and arterial 
stiffness 106.
14
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Obesity and Arterial Elasticity
Obese individuals with excess abdominal fat are at a particular risk for
negative health consequences 59. Studies have shown that adipose tissue in general, 
and visceral adiposity in particular, are key regulators of inflammation 132. The 
inflammatory response to the body’s increased amount of fat may have a negative 
effect on endothelial physiology, which may lead to the formation of atherosclerotic 
plaque4. Adipose tissue secretes proinflammatory cytokines, such as tumor 
necrosis factor-alpha (TNF-a) and interlukin-6 (IL-6), and influences endothelial 
function by promoting the expression of adhesive molecules, which are central in 
the early stages of the atherosclerotic process l34.
Ziccardi et al. examined the effect of weight loss on circulating levels of 
proinflammatory cytokines and on endothelial function in healthy obese women 134. 
The main finding from this study was that circulating levels of TNF-a, IL-6, 
vascular cellular adhesive molecule-1 (VCAM-1), intracellular adhesive molecule-1 
(ICAM-1), and P-selectin were elevated in obese women and positively correlated 
with central adiposity. Weight loss in these subjects resulted in a significant down 
regulation of the inflammatory state and ameliorating endothelial dysfunction.
These results agree with Tchemof et al. who examined the effects of weight loss on 
plasma CRP levels in obese postmenopausal women. They found that fat loss was 
associated with proportional reductions in CRP levels 116. Another study found that 
body fat measures were among the strongest predictors of large arterial stiffness in 
young and older adults 125. There also existed a strong association between weight 
gain and progression of arterial stiffness, as well as between weight loss and 
regression of arterial stiffness 124.
15
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These findings suggest that weight loss could be a safe way to down regulate 
the expression of inflammation in an attempt to preserve the integrity of the 
vasculature.
Inflammation and Arterial Elasticity
It has been shown that there is a reduced arterial elasticity in patients with
autoimmune and inflammatory diseases, such as rheumatoid arthritis 130. 
Inflammation is a cardiovascular disease risk factor often associated with 
endothelial dysfunction 62, and loss of arterial compliance in both the large and the 
small arteries 130. Advancing age is associated with increased expression of various 
inflammatory markers in the vascular wall interleukin-1 (IL-1), interleukin-6 (IL-6), 
and Tumor Necrosis Factor-a (TNF-a), leading to vascular wall changes and 
eventually nitric oxide bioavailability 122. The up regulation of the expression of 
adhesion molecules in the vascular wall is the initiating event in this process and 
allows leukocytes and monocytes to penetrate into the subendothelium space where 
TNF-a, IL-6, and other cytokines are released, resulting in additional circulating 
cytokines21. High sensitive C-reactive protein (hsCRP) is a systemic marker for 
inflammation that has been associated with the risk for cardiovascular disease 12, 
and is released by the liver in response to IL-6 21. Duprez et al. support the 
hypothesis that hsCRP is associated with large arterial, but not with small arterial 
elasticity in asymptomatic individuals21.
Wong et al. examined both large and small arterial elasticity in patients with 
rheumatoid arthritis (RA) and in healthy controls 130. In addition, vascular health 
was compared and related to traditional vascular risk factors and measures of RA
16
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disease activity and inflammation. As expected, hsCRP and VCAM-1 values were 
significantly elevated in RA subjects compared to controls. There was an inverse 
association with large and small arterial elasticity in both groups, with RA patients 
having a lower average large and small arterial elasticity. These values were also 
inversely correlated with markers of inflammation. This study found that vascular 
function is abnormal in RA, with reduced large and small arterial elasticity, and 
inversely associated with measures of inflammation. A study by Grey et al. showed 
that a reduction in large arterial elasticity of 2 ml/mmHgXIO was associated with a 
33% increase in cardiovascular events36.
The early detection of vascular damage and the identification and treatment 
of vascular inflammation and inflammatory diseases may reduce the personal and 
economic burden of increased disorders secondary to inflammatory diseases. Tools 
such as PCA can be used easily to noninvasively examine the integrity of the 
vasculature, and hsCRP can be measured with a simple blood test to examine any 
potential systemic inflammation.
Aerobic Exercise and Arterial Elasticity
Regular exercise could influence endothelial function and may improve the
cardiovascular risk profile. The cardiovascular benefits of exercise are well 
established, including improving endothelial function in patients with, 
hypercholesterolemia60, metabolic syndrome56, lowering blood levels of low 
density lipoprotein cholesterol (LDL-C)22, and decreasing risk for chronic heart 
failure37.
17
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It has been suggested that aerobic exercise improves endothelial function in
different vascular beds. However, the beneficial effects on the vasculature were not
maintained in the absence of exercise, hypothesizing the importance of continuous
exercise31. Physical conditioning has beneficial effects on the cardiovascular
101system and the immune system . Regular exercise diminishes the occurrence of 
developing ischemic heart disease, and reduces the chance of coronary mortality or 
morbidity after an acute myocardial infarction1. Several examinations have 
provided strong evidence that regular physical exercise attenuates the age-related
"30 4 0  1 1 0  1 1 ^vascular changes ’ ’ , proposing that physical exercise can counterbalance
the effects of aging on the atherosclerotic vascular process. Jensen-Urstad et al. 
examined the elasticity of large arteries in elderly men with and without a life-long 
history of regular strenuous endurance exercise43. Arterial elasticity was measured 
using ultrasound. They found that subjects with a life-long history of exercise had 
more elastic arteries than their control counterparts. However, this study only 
investigated very physically fit and sedentary individuals, had a very small sample 
size, and limited their analysis to only men. The results from this study cannot be 
generalized to other physical activity levels or populations.
The suggested mechanism for the increase in arterial compliance with 
aerobic exercise is that the increased pulse pressures and mechanical distension 
during the exercise sessions “stretches” collagen fibers and modifies their cross- 
linking, thereby increasing arterial compliance. Arterial compliance can also be 
altered over a short time period, even acutely, via modulation of the sympathetic- 
adrenergic tone of smooth muscle cells in the arterial w all115.
18
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Regular aerobic exercise training is efficient in delaying and attenuating 
arterial stiffness in healthy adults l14,115. However, the specific effect of resistance 
training on the vasculature still remains controversial.
Resistance Exercise and Arterial Elasticity
In recent years, resistance exercise prescription has become more widely
acceptable in the various therapy settings, including cardiac rehabilitation settings. 
This type of exercise prescription is used most often in the prevention and 
attenuation of loss of bone mineral density and other related risks, such as 
predisposition for falling and functional disability26. Resistance training is strongly 
recommended as a preventative intervention in the elderly to enhance quality of life
D O
and activities of daily living . It is reasonable to suggest that with increased 
muscular strength and greater bone mass, the elderly would be more physically 
active and gain some of the same beneficial effects on the vasculature as seen with 
endurance exercise.
However, a cross-sectional study by Miyachi et al. demonstrated that 
resistance training was associated with lower central arterial compliance, and that 
the age-related reductions in arterial compliance were greater in the resistance 
trained men than in sedentary men, suggesting that resistance exercise does not have 
similar favorable effects as endurance training74. Another study by the same 
author75 examined a resistance training intervention lasting four months. The 
subjects participated in three supervised sessions each week for four months and 
detraining for a subsequent four months. The control group was instructed not to 
alter their normal levels of activity throughout the training period. The study
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showed that arterial elasticity decreased in the resistance-training group, but not in 
the control group. The decrease in arterial elasticity returned to baseline levels 
during the detraining period, confirming that the change in arterial elasticity was 
due to the resistance training. While these past two studies only examined men, it 
has been shown that similar vascular responses with resistance training also can be 
observed in healthy women 19.
A possible explanation for this reduced central arterial compliance in 
resistance trained men may be that the acute intermittent elevations in arterial blood 
pressure in the cardiothoracic region during resistance exercise may result in 
chronic increases in the smooth muscle content of the arterial wall and the load- 
bearing properties of collagen and elastin. During each bout of resistance exercise, 
arterial blood pressure is known to increase as high as ~320/250mmHg. Another 
potential physiological mechanism is that the higher sympathetic nervous system 
activity in resistance-trained men may have acted to reduce arterial compliance by 
providing chronic restraint on the arterial wall through greater sympathetic 
adrenergic vasoconstrictor tone74.
Cortez-Cooper et al. examined the effects of 11 weeks of high intensity 
resistance training on arterial stiffness and wave reflection in women 19. They 
examined 23 healthy women (29 ± 1 years) that were either sedentary or 
recreationally active, but that did not participate in resistance training. The subjects 
performed a variety of lower and upper body exercises. The first 4 weeks of the 
training program, the subjects performed three sets of ten-repetition exercises until 
concentric failure. The following 4 weeks, three sets of five-repetition exercises
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were completed. The last 3 weeks of the training intervention consisted of 
supersets, upper body exercise paired with lower body exercise, using six sets of 
five repetitions in which the weights increased for four sets followed by a decrease 
for two sets. Carotid augmentation index and pulse wave velocity as a measure of 
large arterial stiffness, increased significantly for the training group compared to 
that of the control group. Carotid-femoral PWV increased significantly in both 
groups, and was attributed to a possible increased physical activity for the control 
subjects due to seasonal variations.
One recent study showed that twelve weeks of resistance training performed 
five times per week did not alter central arterial compliance, suggesting a dose 
response relationship with resistance training 95. There still exist gaps involving the 
physiological mechanism(s) responsible for the changes in the vasculature with 
resistance training. Other studies have examined the acute effects of resistance 
training on arterial compliance. During exercise, plasma norepinephrine levels are 
elevated after an acute bout of resistance exercise, which may suggest the possibility 
that sympathetic vasoconstrictor tone may also be elevated after exercise . With 
this as background information, DeVan et al. examined the acute effects of one bout
90of resistance exercise on central arterial compliance . Sixteen healthy sedentary or 
recreationally active adults were studied under parallel experimental conditions on 2 
separate days. The order of experiments was randomized between resistance 
exercise (9 exercises at 75% of 1RM) and sham control (seated rest in the exercise 
room). Arterial compliance was determined noninvasively with a combination of 
ultrasound imaging at the common carotid artery with simultaneous applanation of
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tonometrically obtained arterial pressures from the contralateral carotid artery. 
Central arterial compliance was decreased immediately and 30 minutes after 
resistance exercise. These measurements returned to baseline levels within 60 
minutes after resistance exercise. So, the acute effects of resistance exercise on 
arterial stiffness are transient in nature, and the reduced elastic properties of the 
large arteries could be a result of the chronic effects of resistance exercise 
training.
Examining additional regional arterial stiffness effects after exercise, 
Kingwell et al. showed that a 30-minute bout of moderate cycling using both legs, 
increased arterial elasticity 30 minutes after the exercise49. They hypothesized the 
possible influence of systemic (e.g. sympathetic nervous activity, circulating 
hormones) and regional (e.g. endothelial-derived vasoactive substances) factors in 
changing the vascular tone. So, Sugawara et al. hypothesized that the exercise-
1 ft7induced decrease in arterial stiffness would mainly be caused by regional factors 
The effects of low-intensity single-leg exercise on regional stiffness were examined 
in young men. Their findings suggest that the acute decrease in stiffness in the 
midsized conduit artery with a low-intensity, short-duration exercise may be 
mediated by regional factors rather than by systemic factors.
Bertovic et al. suggested that resistance training was associated with 
increased arterial stiffness and high blood pressure9. They also suggested the 
possibility that the higher blood pressure among the resistance trained individuals 
promoted increases in arterial stiffness. Other studies have reported that the blood
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pressure response during eccentric contractions is smaller than that during
85 117concentric contractions ’
With the previously information at hand, Okamoto et al. examined the 
effects of eccentric resistance training and concentric resistance training on arterial 
stiffness in 29 healthy female adults83. This study also examined the change in 
arterial stiffness after detraining to understand the effect of resistance training better. 
The subjects were randomized into an eccentric training group, concentric training 
group, or a sedentary group. The training groups performed resistance training three 
times per week for eight weeks. The nondominant arm was selected for training to 
minimize the effects of daily activities. The training consisted of 5 sets of 10 
repetitions of an arm curl. Prior to the training, 1RM in arm curling was 
determined. The load was set to 100% of 1RM for eccentric training and 80% of 
1RM for concentric training. Brachial blood pressure, brachial-ankle pulse wave 
velocity (baPWV), carotid artery intima-medial thickness (IMT) and carotid arterial 
lumen diameter was determined before and after training and after detraining. The 
baPWV before training did not differ between the groups. After eight weeks of 
resistance training, the arterial stiffness in the concentric group increased compared 
with the eccentric group and the sedentary group. However, baPWV, IMT and 
carotid lumen diameter in the eccentric and concentric groups were unchanged by 
eight weeks of resistance training. This suggests that eccentric resistance training 
may be effective as an exercise prescription for this population. More studies are 
needed in the future to examine the effect of whole body eccentric resistance 
training in an older population.
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Maeda et al. examined the effect of leg resistance training on arterial 
stiffness in older men 65. The subjects completed three sets of knee extension and 
flexion (10 repetitions at 60% 1 RM) twice per week for 12 weeks. Resistance 
training had no effect on arterial stiffness as assessed by aortic pulse wave 
velocity.
Aerobic Exercise and Resistance Exercise Combined
Regular aerobic exercise and resistance training are often recommended for
the prevention and treatment of cardiovascular disease and frailty associated with 
aging. Regular endurance-type exercises seem to have beneficial effects for 
preventing or attenuating arterial stiffness in middle-aged and older adults76,115. In 
contrast to the beneficial effects seen with endurance exercise, resistance training is 
associated with an increase, rather than a decrease in arterial stiffness74. So, regular 
aerobic exercise and resistance training seem to exert opposite effects on the elastic 
properties of the arterial wall. The following studies will examine the effects of 
performing a combination of endurance and strength training on arterial elasticity.
Cook et al. examined central and peripheral arterial compliance in middle- 
aged and older rowers and in age-matched sedentary controls 18. They used a cross- 
sectional design to determine arterial compliance of 15 healthy, habitual rowers and 
15 healthy sedentary controls. The mean age for the two groups was 50 years and 
52 years, respectively. The rowers had been training for approximately five years, 
once per week. The two groups were matched for age, body composition, blood 
pressure, and metabolic risk factors. Central arterial compliance was determined 
with simultaneous ultrasound and applanation tonometry on the common carotid
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artery. Central arterial compliance and carotid P-stiffness index was lower in 
rowers than in sedentary controls. There were no group differences in peripheral 
arterial compliance. These results suggest that regular rowing exercise in middle- 
aged and older adults is associated with a favorable effect on central arterial 
compliance, and that simultaneous performed endurance training may negate the 
stiffening effect often seen with resistance training.
The combined effect of endurance and resistance training has also produced 
favorable effects in other cardiovascular aspects. Four months of combined 
endurance and resistance training has shown to have an anti-inflammatory effect in 
patients with moderate to severe heart failure due to coronary artery disease I7.
After eight weeks of training involving a combination of cycle ergometry, treadmill 
walking and resistance training, there was an improvement in resistance vessel 
endothelial vasodilator function in patients with type 2 diabetes67. Another 
examination by the same author, concluded that a combination of aerobic and 
resistance training improves endothelium-dependent and -independent vascular 
function in patients with chronic heart failure68. Kawano et al. examined the effects 
of moderate resistance training as well as a combination of resistance and endurance 
training on arterial compliance45. Thirty-nine healthy young men were assigned 
either to moderate intensity training, combination resistance training and endurance 
training or a sedentary control group. Carotid arterial compliance (assessed by 
simultaneous carotid ultrasound and applanation tonometry) decreased 
approximately 20% after the moderate resistance training, with no changes observed 
in the combination or control group. This suggests a combination of resistance and
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endurance training should be performed in order to negate the stiffening of the 
arteries.
Summary
A growing body of evidence suggests that obese individuals with excess 
abdominal fat are at higher risk for cardiovascular disease 59. Furthermore, visceral 
adiposity in particular has been identified as a key regulator of inflammation, as is 
secreting proinflammatory cytokines, such as TNF-a, IL-6, and CRP. These 
markers further induce endothelial expression of adhesion molecules, which are 
central in the beginning stages of atherosclerotic plaque build up 134. Studies have 
reported higher circulating levels of proinflammatory cytokines in obese men 27 and 
women 134. Obesity is associated with hypertension and increased concentration of 
circulating inflammatory markers 21 ’134, which further is associated with 
atherosclerosis and hardening of the arteries, i.e. arterial stiffness 1U.
Weight loss has been shown to down regulate the inflammatory state and 
ameliorate endothelial function in women 134, and in hypertensive and normotensive 
m en21. Endurance training has been shown to decrease blood pressure25 and 
increase arterial elasticity in young healthy men in both cross-sectional,81 and 
intervention studies 16,50,81. The effect of resistance training on arterial elasticity is 
still unclear, with reports of no effect 65,95, as well as an observed increase in arterial 
stiffness in both cross-sectional 74,84 and intervention 75 studies. The newest 
approach introduced in the literature is to perform a combination of both endurance 
and strength training, as this has showed favorable outcomes thus far 18,45.
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CHAPTER III 
METHODOLOGY
The primary purpose of this study was to examine the effect of twelve weeks 
of resistance training on large (Cl) and small (C2) arterial elasticity in 
premenopausal women, and a group of healthy controls. The secondary purpose 
was to examine the relationship between C-reactive protein and arterial elasticity in 
these women. Subjects were healthy women between the ages of 19 and 48 years, 
and who were not taking hormone replacement therapy, antihypertensive drugs, or 
hormonal birth control. Measurement variables included large and small arterial 
elasticity, the inflammatory marker, CRP, and muscular strength (1-RM) for seven 
resistance exercises.
Subjects
The subjects for this study were healthy, premenopausal women between the 
ages of 19 and 48 years of age (n = 32). The subjects were recruited from the 
University of Oklahoma, Norman campus and the surrounding areas via recruitment 
flyers posted in public areas and flyers mailed to prospective subjects at the 
University of Oklahoma, Norman campus (Appendix A). Subjects read and signed 
a written informed consent as approved by the University of Oklahoma Institutional 
Review Board (Appendix B). All methods and procedures were approved by the 
University o f Oklahoma Institutional Review Board (IRB No. 11551) (Appendix C). 
Approximately half of the subjects enrolled in the study in the fall, whereas the 
other half enrolled after Christmas break and trained through the spring. Most of 
the control subjects were recruited after Christmas.
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Inclusion Factors
1. The subjects were healthy premenopausal women between the ages of 18 
and 50 years.
2. Subjects were free of cardiovascular disease, peripheral arterial disease, 
coronary heart disease, non-smokers, not pregnant, not on hormone 
replacement therapy, not taking antihypertensive drugs or any hormonal 
birth control.
3. Subjects had the cognitive ability to give written consent and to follow 
the given guidelines.
Exclusion Factors
1. Subjects with a history of cardiovascular disease, coronary heart disease, 
and peripheral arterial disease were not allowed to participate.
2. Women with diabetes mellitus were not allowed to participate.
3. Those who were currently taking hormone replacement therapy or taking 
antihypertensive drugs, hormonal birth control, or were pregnant, were 
not allowed to participate.
Research Design
This study employed a mixed factorial repeated measures design as a control 
group and a training group was assessed before and after the 12 week training 
period. The subjects were screened during a telephone interview, where the 
procedures were reiterated again. Once cleared, the subjects were assigned either to 
a resistance-training group (T, n = 21) or a control group (C, n = 11). The training 
subjects were assigned either to a morning session (6:30am; 7:15am) or an 
afternoon session (4:30pm; 5:15pm) based on the subject’s availability. The
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training sessions were held on Monday, Wednesday, and Friday in the 
Neuromuscular Laboratory, located in the Department of Health and Exercise 
Science on the University of Oklahoma-Norman campus.
The first visit to the Bone Density Laboratory, also located at the 
Department of Health and Exercise Science on the University of Oklahoma-Norman 
campus, consisted of completing the informed consent and questionnaires about 
calcium intake, menstrual history, health status questionnaire (Appendix D), a 
baseline total body DXA scan, and baseline measures of large and small arterial 
elasticity. Following the first visit, an appointment was made to visit Goddard 
Health Center at the University of Oklahoma-Norman campus for a baseline blood 
draw. The subjects began a twelve week supervised resistance-training program at 
the Neuromuscular Laboratory at the Department of Health and Exercise Science. 
Strength was assessed by 1-RM at baseline, after six weeks of training to apply 
progressive overload, and then at twelve weeks. Blood draws, DXA scans, and 
measures of arterial elasticity were assessed at baseline and at the end of twelve 
weeks of training.
Resistance Training
The resistance training exercises primarily targeted sites at the hip and leg,
and lower leg muscle groups. The following exercises were selected:
* Hip flexion (standing position on a multi-hip machine)
* Hip extension (standing position on a multi-hip machine)
* Hip abduction (standing position on a multi-hip machine)
* Hip adduction (standing position on a multi-hip machine)
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* Supine leg press
* Biceps curl (using dumbbells)
* Triceps extension (using dumbbells)
* Calf (using a plate-loaded weight machine)
* Shin (using a plate-loaded weight machine)
The resistance exercises were performed using isotonic weight training 
equipment (Cybex Inc., Medway, MA) with a concentration on the hips, tibialis 
anterior and soleus muscles. The first week was familiarization of the equipment 
and exercises to prevent potential injuries. Trained personnel demonstrated proper 
use of equipment, and on week two, a 1-RM was determined. The biceps curl and 
the triceps extension exercises were not tested for 1-RM, and the weight selected for 
the exercises was chosen at the subject’s own discretion. A proper warm-up was 
encouraged before the each exercise session, either walking or riding the stationary 
bicycle. The 1-RM was obtained by finding the maximum load that the subject 
could move with good form through the entire range of motion. Two warm-up sets 
with 8-10 repetitions and 3-5 repetitions with progressing load were completed 
before the first 1-RM attempt. The 1-RM was found within 5 attempts, with 1- 
minute rest between each attempt. The 1-RM testing was supervised and recorded 
by trained personnel (Appendix E).
The subjects performed two sets of eight repetitions at 80% of their 1-RM 
for all hip exercises. The remaining exercises consisted of three sets of eight 
repetitions at 80% of their 1-RM. Each exercise session was completed in about 30 
minutes. During each training session, the subject personally recorded the number
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of repetitions, amount of weight lifted and the number of sets for each of the 
exercises on a computer-generated work out log that specified the correct amount of 
weight to be used (Appendix E). Trained personnel supervised all exercise sessions, 
encouraged participants, and helped to change the weights whenever necessary.
The first week of training consisted of familiarization with light weights for the 
subjects. During the second week, a 1-RM was obtained over two training sessions. 
The subjects performed 1-RM for half the exercises during session one and lifted 
weights for the resistance exercises not tested that day. The reminder of the 1-RMs 
were performed during session two with subjects lifting weights for the exercises 
tested during session one. The third session of the second week was the subjects 
first day of training at 80% of their 1-RM. The same protocol was followed for the 
mid-and post testing.
The week by week training schedule is depicted below.
Wk.l Wk.6 Wk.12
Fam. 1-RM Load Load Load Load 1-RM Load Load Load Load 1-RM
Body Composition Measurements
Dual energy x-ray absorptiometry (DXA) (GE Medical Systems, Lunar
Prodigy) was used to determine body composition before and after the training 
period. DXA is a noninvasive measuring tool, which requires little participation 
from the subjects. The subjects were asked to remove any metal or clothing 
containing metal, before laying down in a supine position on the DXA platform.
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The subject must lie still as the scanner arm moves across the body in a posterior to 
anterior direction.
The DXA scan is based on high and low energy levels of X-ray passing 
through tissue, and the exposure to radiation is minimal. The low energy beam can 
only pass through the soft tissue, whereas the high-energy beam can pass through 
bone. Standard protocol was followed to ensure high accuracy. The analyses of the 
scans were analyzed using the encore software (GE Medical Systems, version 
8.50.093) (Appendix F). Quality Assurance procedures were performed every day 
to ensure proper calibration prior to scanning.
The DXA scan provided information on the subject’s BMD (g/cm2), bone 
mineral content (g), and percent body fat. Qualified technicians performed all scans 
and analyses. The coefficient of variation for total body BMD using DXA in the 
Bone Density Research Laboratory is 1%.
Pulse Contour Analysis (PCA)
Arterial stiffness was measured using the HDI/Pulsewave™CR-2000 and the
CVProfilor™ DO-2020 CardioVascular Profiling System (Hypertension 
Diagnostic, Inc., Eagan, Minnesota, USA). The device consisted of an oscillometric 
blood pressure module, a noninvasive Arterial PulseWave™ Sensor and a 486-75 
MHz computer and medical electronics, which included a touch screen and 
software. The blood pressure cuff that was placed around the patient’s left upper 
arm was connected to the rear panel of the unit with a hose.
The height and weight was measured and entered into the 486-75 MHz 
computer. The subject rested in a supine position for approximately five minutes.
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An appropriate-sized cuff was wrapped around the subject’s upper left arm. A rigid 
plastic wrist stabilizer was placed on the subject’s right wrist to minimize any 
movement and stabilize the radial artery during the three 30-sec collection of blood 
pressure waveform data (Appendix G). A non-invasive Arterial PulseWave™ 
Sensor was positioned on the surface of the skin overlying the right radial artery at 
the point of the strongest pulsation to capture an analog blood pressure waveform. 
The sensor was adjusted to the highest relative signal strength, without occluding 
the artery. Three consecutive trials were performed, since one-way analysis of 
variance showed no significant differences between the trials, the trials were 
averaged for the subsequent analyses.
Q<> Q 1
This noninvasive instrument has proven to be a reliable ’ 
measurement of large and small arterial elasticity, and useful in its method for 
assessing atherosclerosis 58. The investigator’s precision of the PCA measurements 
was determined by measuring 9 healthy men and women two different times, 2-3 
days apart. To avoid potential diurnal variations, the subjects were tested in a fasted 
and rested state at the same time of day for both visits. The coefficient of variation 
for Cl and C2 measurements obtained by the same operator, were 12% and 12%, 
respectively. The intraclass correlation coefficients for Cl and C2 were 0.797 and
0.984, respectively.
Blood Sampling
Venipuncture blood collection from the antecubital vein occurred in the 
morning after at least eight hours of fasting, and with the subjects in a resting 
condition. A certified phlebotomist or a registered nurse at Goddard Health Center
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performed the blood draws. A sample of 6 ml of blood was collected. The samples 
were centrifuged and serum samples were aliquoted into 0.5 ml vials and frozen at 
-70°C until the time of the C-reactive protein (CRP) assays. To reduce protein 
degradation, the serum was only thawed once prior to the assays.
Biochemical Assays
CRP was measured in duplicate by enzyme-linked immunosorbent assay
(ELISA) kits (Alpco Diagnostics, Salem, NH). The enzyme absorbance was
determined using a spectrophotometer (Packard, Downers Grove, IL) and the CRP
concentration was calculated using a standard calibration curve. CRP units are
reported in mg/1. The normal range for healthy adults is 0.068 -  8.2 mg/1. The
intra-assay coefficient of variation was 6.7% and 8% and the inter-assay coefficient
of variation was 16%.
The CRP assay protocol was completed according to the following
guidelines (Appendix H):
1. Allow serum and kit to come to room temperature.
2. Wash Buffer: (1:10) 450 ml dH20 + 50 ml wash buffer.
3. Antibody Solution: (1:100) 100 pi antibody + 10 ml wash buffer.
4. Sample Dilution (1 TOO) 10 pi sample + 990 pi dilution buffer.
5. Pipette 10 pi of the Standards (A-F), Controls (high and low), and 
Unknowns followed by 100 pi of the antibody solution.
6. Cover micro well samples with sealing tape, place and attach with foam 
and tape onto Innova 2000 platform shaker (New Brunswick Scientific,
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Edison, NJ), and incubate at room temperature for 60 minutes at 300 
rpm.
7. The microwells are washed 5 times with 250 pi of wash solution using 
the MultiWash Microplate Washer (Tri Continent, Grass Valley, CA). 
After the wash the micro wells are blotted dry.
8. Add 100 pi of the diluted antibody to each well and incubate for 60 
minutes on the Innova 2000 platform shaker as previously described.
9. The microwells are washed 5 times with 250 pi of wash solution as 
previously described.
10. Add 100 pi of Substrate Solution to each well and incubate at room 
temperature for 10 minutes in the dark.
11. Add 50 pi of Stop Solution to each well.
12. Read absorbance at 450 nm in the Spectracount Plate Reader (Packard, 
Downers Grove, IL).
Data Analyses
All descriptive analyses were reported in mean ± standard error (SE) for the 
dependent variables. The effects of the training on large and small arterial elasticity 
and CRP were analyzed by two-way (group X time) repeated measures analysis of 
variance (ANOVA). Pearson Product Moment Correlation Coefficients were 
computed to determine the relationships among the arterial elasticity variables and 
CRP. Percent changes from baseline in arterial elasticity, CRP and strength were 
calculated (%A = (post-pre/pre)*100) and a one-way ANOVA was used to examine 
any significant group differences. Analysis of Covariance (ANCOVA) was used to
35
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
examine large arterial elasticity responses after adjusting for body weight, BMI, and 
% body fat. The level of significance was set at p < 0.05. All statistical procedures 
were performed by SPSS 11.5 software (Chicago, IL).
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CHAPTER IV 
RESULTS AND DISCUSSION
The purpose of this study was to examine the effects of a 12-week resistance 
training program on large (Cl) and small (C2) arterial elasticity and the 
inflammatory marker C-reactive protein (CRP). Subjects were healthy 
premenopausal women, between the ages of 19 and 48 years, who were not taking 
any hormonal contraceptives. Primary outcome measures included large and small 
arterial elasticity and the biochemical marker of inflammation, CRP.
Subject Characteristics
A total of 43 subjects were recruited, however 7 subjects did not start the
program for a variety of reasons. The reasons were time commitment, a primary 
focus on lower body exercises in the training program, and not being able to contact 
subjects after the first visit. Two training subjects had to withdraw after eight weeks 
due to family illness and one control could not participate in post testing due to 
family illness. Thirty-four subjects completed the 12 weeks; however, two control 
subjects could not participate in the 1-RM post testing due to physical injuries 
outside the study, and were excluded from the statistical analyses. Thirty-two 
subjects completed the 12 weeks of the study and were used in the analyses. The 
subjects in the intervention group completed ~ 85 % of the scheduled training 
sessions.
Subjects were assigned to experimental groups based on their availability to 
train in the morning or in the afternoon. Table 1 displays the baseline physical
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characteristics. There were no significant differences (p > 0.05) between groups for 
these variables at baseline.
Table 1. Physical Characteristics at Baseline for each Group.
Group
Variable Training (n = 21) Control (n = 11)
Age (yrs) 33.2 ±2.1 36.8 ± 3.2
Body Weight (kg) 74.2 ± 4.5 67.0 ±3.3
Height (cm) 166.1 ± 1.1 165.6 ±2.1
BMI (kg/m2) 26.6 ± 1.4 24.4 ±1.1
Body Fat (%) 36.5 + 1.8 35.7 ±3.1
BSA (m2) 1.8 ± .05 1.7 ± .04
FFM (g) 42684 ± 1735.3 39103 ± 1254.3
Values are means ± SE. E3MI; Body Mass Index, BSA; Body Surface Area, FFM; Fat Free 
Mass.
There were no significant (p > 0.05) changes from baseline in BMI, weight, %body 
fat, or fat free mass for any of the groups.
Cardiovascular Responses to Training
Table 2 shows the mean baseline and post-test cardiovascular measures for
the training and the control groups. Repeated measures ANOVA (time x group) 
revealed that diastolic blood pressure had no significant group (p = 0.828), or 
group*time interaction effects (p = 0.947), but did show a significant time effect (p 
= 0.049). Diastolic blood pressure decreased over time for both groups. Systolic 
blood pressure showed no group (p = 0.641) or group*time interaction effects (p = 
0.665), but did show a trend for time effect (p = 0.073). Heart rate, pulse pressure, 
systemic vascular resistance, and total vascular impedance did not significantly (p > 
0.05) change from baseline to the end of the training period. The percent changes of 
these variables are shown in Table 3.
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Table 2. Cardiovascular Variables.
Group
Training (n = 21) Control (n = 11)
Variable Pre Post Pre Post
RHR (beats/min) 66.3 ± 1.9 65.2 ± 2.4 61.7 ±2.9 58.9 ±3.1
SBP (mmHg) 118.9 ±2.4 116.2 ±3.0 117.9 ±3.0 113.6 ± 2.1
DBP (mmHg) 69.0 ±2.0 66.6 ±2.1* 69.6 ±2.7 67.4 ±2.1*
Hypertension (%) 19 9.5 18 9
PP (mmHg) 49.8 ± 1.2 49.5 ± 1.3 48.2 ± .9 46.1 ± .8
C1 (ml/mmHg x 10) 15.9 ± .6 17.2 ± 1.1* 16.0 ± .9 18.1 ±1.3*
C2 (ml/mmHg x 100) 7.6 ±.5 7.8 ±.6 8.2 ± .9 8.6 ± .9
CRP (mg/L) 2.2 ±.7 2.53 ±.6 1.3 ± .6 1.5 ± .8
SVR dyneseccm'5 1263.9 ±63.2 1167.4 ±47.6 1334.0 ±57.2 1284.6 ±44.9
TVI dyne sec cm'5 126.5 ±6.4 120.2 ±5.4 128.4 ±5.3 120.5 ±3.9
*p < 0.05, Values are mean ± SE. RHR; Resting Heart Rate, SBP; Systolic Blood Pressure,
DBP; Diastolic Blood Pressure, Hypertension defined as SBP/DBP > 130/85 mmHg, 
PP; Pulse Pressure,C1; Large Arterial Elasticity, C2; Small Arterial Elasticity,
CRP; C-Reactive Protein, SVR; Systemic Vascular Resistance,TVI; Total Vascular 
Impedance.
Table 3. Mean ± SE Percent Change in Cardiovascular Variables After Training.
Group
Variable Training (n = 21) Control (n = 11)
RHR (beats/min) -1.03 ±3.51 -4.52 ± 1.85
SBP (mmHg) -2.04 ± 2.01 -3.38 ± 1.38
DBP (mmHg) -3.16 ± 1.77 -2.61 ± 2.29
PP(mmHg) 0.18 ±2.92 -4.21 ± 1.03
SVR dyne sec cm'5 -5.38 ± 3.67 -3.15 ±2.47
TVI dyne sec cm'5 -2.34 ± 4.84 -5.16 ±3.44
RHR; Resting Heart Rate, SBP; Systolic Blood Pressure, DBP; Diastolic Blood Pressure, 
PP; Pulse Pressure, SVR; Systemic Vascular Resistance, TVI; Total Vascular Impedance.
Large and Small Arterial Elasticity
Based on the two-way (time x group) repeated measures ANOVA, there was 
no significant group effect for Cl (p = 0 .723), but a significant time effect with an 
increase in Cl (p = 0 .023) from pre to post test, and no significant interaction
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between time*group (p = 0.634). The same analyses for C2 revealed no significant 
group (p = 0.497), time (p = 0.537), or significant time*group interaction effects 
(p = 0.764). Cl showed an increase of 9% for the training group and 13% for the 
control group, whereas C2 revealed a non-significant (p > 0.05) increase of 5.8% 
and 11.5% for the training group and the control group, respectively. The relative 
changes in Cl for both groups exceeded the CV for Cl (6.7%) determined in the 
precision analysis.
After using Analysis of Covariance (ANCOVA) to adjust for body weight, 
BMI, and percent body fat in separate analyses, there was no longer a significant 
time effect for Cl (p > 0.05). After adjusting for age, there still was a significant 
time effect for Cl (p = 0.043), but no significant group (p = 0.377) or group*time 
interaction effects (p = 0.468). The unadjusted Cl and C2 responses to 12 weeks of 
training are presented in Figure 1 and Figure 2.
Figure 1. Large Arterial Elasticity (Cl) Responses to 12 Weeks of Training.______
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* Significant time effect, p < 0.05, Values reported as Mean ± SE.
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Figure 2. Small Arterial Elasticity (C2) Responses to 12 Weeks of Training.
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No significant differences, p > 0.05. Values reported as Mean ± SE.
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Age and Arterial Elasticity
Since there was a large age range the study, the relationships between age
and arterial elasticity variables were examined using Pearson Product Moment
Correlation Coefficients. There was a significant negative correlation between Cl
and age (r = -0.381, p = 0.032), indicating as age increased the elasticity of the large
arteries decreased. There was no significant relationship between age and small
arterial elasticity (r = -0.101, p = 0.581). After grouping the subjects into two age-
groups; (1): 19-33 years (n = 16) and (2): 34-48 years (n = 15), a one-way ANOVA
revealed that the older group had significantly stiffer large arteries (p = 0.002), but
not small arteries (p = 0.119) compared to the younger group. Figure 3 shows the
age group differences for large and small arterial elasticity.
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Figure 3. Baseline Age Group Differences for Large and Small Arterial Elasticity.
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CRP Responses to Training
Two-way Analysis of Variance with repeated measures (time x group) was
completed to examine CRP responses to training. There were no significant group 
(p = 0.346), time (p = 0.641), or time*group interaction effects (p = 0.899). The 
non- significant percent change in CRP was 83.9% and 9.1% for the training group 
and the control group, respectively. After excluding three outliers, the percent 
change in CRP was 46.8% for the training group. Figure 4 displays the CRP 
responses to training.
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Figure 4. CRP Responses to 12 Weeks of Training.
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Values reported as Mean ± SE.
Pearson Product Moment Correlation Coefficients were computed to 
examine the relationships between CRP and cardiovascular and body composition 
variables. As shown in Table 4, body weight, BMI, and percent body fat were 
positively related (p < 0.05) with CRP.
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Table 4. Baseline CRP Correlations for All Subjects.
C-Reactive Protein (mg/L)
Variable r  p-value
Age (yrs) 0.116 0.528
SBP (mmHg) 0.313 0.081
DBP (mmHg) 0.197 0.279
Pulse Pressure (mmHg) 0.306 0.089
SVR dyneseccm'5 -0.089 0.628
TVI dyne sec cm"5 0.035 0.848
Body Weight (kg) 0.44 0.012*
BMI (kg/m2) 0.474 0.006**
Body Fat (%) 0.507 0.003**
C1 (ml/mmHg x 10) -0.163 0.373
C2 (ml/mmHg x 100) -0.183 0.317
**p<0.01, *p<0.05. SBP; Systolic Blood Pressure, DBP; Diastolic Blood Pressure, SVR; 
Systemic Vascular Resistance, TVI; Total Vascular Impedance, BMI; Body Mass Index, 
C1; Large Arterial Elasticity, C2; Small Arterial Elasticity.
Muscular Strength Responses to Training.
The mean muscular strength values (kg) for the seven exercises (hip flexion,
hip extension, hip abduction, hip adduction, leg press, calf raises, and shin exercise) 
are shown in Table 5. There were no significant differences (p > 0.05) between 
groups at baseline for any of the strength variables, and the relative changes in 
strength are presented in Figure 5 and 6.
Table 5. Muscular Strength at Baseline and After 12 Weeks of Training.
Group
Training (n = 21) Control (n = 11)
Variable Pre Post Pre Post
Hip Flexion 48.8 ±1.9 85.4 ± 3 .7 **m 51.6 ±2.0 57.0 ± 3.8
Hip Extension 65.3 ± 2.9 95.2 ± 3.2**J 72.3 ±4.0 75.4 ± 4.8
Hip Abduction 39.6 ± 1.2 59.2 ± 2 .5 **ttt 40.2 ± 2.0 43.9 ±2.4
Hip Adduction 49.2 ± 1.8 69.0 ± 3.3*** 52.4 ± 2.0 53.2 ± 2.7
Leg Press 107.3 + 4.4 144.5 ±8 .0 **ft 101.2 ± 6.1 111.1 ±4.7
Calf Raises 51.6 ±2.7 88.5 ± 4 .5 **ftt 46.2 ± 3.4 58.4 ± 5.7
Shin Exercise 17.9 ±1.1 25.8 ± ,8**t 19.6 ± 1.3 20.3 ± 1.0
tp<0.05, ttP ^ -O I Group effect; **p<0.01Time effect, $p<0.01 Group*Time interaction. 
Values reported as Mean ± SE. Values are expressed in kilograms.
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Two-way (time x group) repeated measures ANOVA was carried out to 
examine the muscular strength changes. There were significant group (p = 0.004), 
time (p = 0.000), and group*time interaction effects (p = 0.000) for hip flexion 
strength, with the training group becoming significantly stronger compared to the 
control group during the course of the training period. The training group increased 
in hip flexion strength 76.9% from baseline whereas the control group only 
increased 10.5%. There was no group effect (p = 0.130), but a significant time 
effect (p < 0.01), and a significant group*time interaction (p <0.01) were found for 
hip extension strength. The training group improved their strength by 44.1% from 
baseline whereas the control group only increased 6.0%. The hip abduction exercise 
showed significant group (p = 0.011), time (p = 0.000), and group*time interaction 
effects (p = 0.000), with a 51.5% increase in strength observed for the training 
group and a 9.4% increase for the control group. Hip adduction strength showed no 
significant group effect (p = 0.087), however it did show a significant time effect (p 
= 0.000) and group*time interaction (p = 0.000). The training group increased their 
strength 41.6% from baseline and the control group increased 1.7%.
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Figure 5. Percent Changes for Hip Exercises from Baseline for Both Groups.
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2523b.
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**p < 0.01, Values reported as Means ± SE.
The same analyses were carried out to examine leg press, calf raise and shin 
exercise strengths. Leg press showed significant group (p = 0.034), time 
(p = 0.000), and group*time interaction effects (p = 0.003), with a 34.6% increase 
from baseline for the training group versus 12% for the control group. When 
examining calf raises, the analyses showed significant group (p = 0.004), time 
(p = 0.000) and group*time interaction effects (p = 0.000). There was a 74.3% 
increase in calf strength from baseline for the training group and a 25% increase for 
the control group. After examining shin strength, no significant group effect was 
detected (p = 0.174), however there was a significant time effect (p = 0.000), and 
group*time interaction (p = 0.001). The training group had a 55.2% increase in shin 
strength from baseline, whereas the control group increased 6.2%.
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Figure 6. Percent Changes from Baseline for Leg Press, Calf Raises and Shin 
Exercise.
90
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** p < 0.01, Values reported as Means ± SE.
The relationship between total workload and C l, C2, and CRP for the 
training group was examined using Pearson Product Moment Correlation 
Coefficients. The analyses revealed no relationship between total workload and Cl 
(r = -0.10, p = 0.965), C2 (r = -0.159, p = 0.492), and CRP (r = 0.083, p = 0.721).
Discussion
The current study examined the effects of resistance training on large and 
small arterial elasticity and the inflammatory marker, CRP, in healthy 
premenopausal women. The uniqueness of this study is the examination of arterial 
elasticity following lower leg resistance training in women. It has been well 
documented in previous research that endurance training increases arterial elasticity 
31,32,43, ii2,115^  thg effect of resistance training on arterial elasticity is still
unclear, with contradictory results documented9’19,20,74,75,83,85,94,9S. Most of the
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studies have shown a decrease in arterial elasticity following resistance training19,74, 
75, whereas others have shown no changes95, or an increase in arterial elasticity49 
The wide range of results leads us to speculate there may be a dose response impact 
that needs further attention.
This study provides some interesting results in regards to the effect of 
resistance training on arterial elasticity in women. To our knowledge, this is the 
first study that examined arterial elasticity after 12 weeks of lower leg resistance 
training in women. The current study did not find the negative effect on the arteries 
that has been previously reported with resistance training. There are studies that 
have reported an increase in arterial stiffness after 4 months of resistance training 75, 
whereas other have found arterial elasticity unchanged after 12 weeks of training95. 
The exact mechanism in which arterial elasticity is modified during resistance 
training is not well understood. It has been suggested that the frequent increase in 
arterial blood pressure 74 and shear stress 94 in the arterial wall during resistance 
training are contributing factors to the often observed decrease in arterial elasticity. 
Other suggestions are greater sympathetic nerve activity, decreased nitric oxide 
bioavailability, and increased levels of vasoconstrictor hormones 19.
Arterial Elasticity
The subjects for this study were healthy, premenopausal women, who did 
not take any hormonal contraceptives. This study showed a significant increase 
over the 12 weeks in large arterial elasticity (p < 0.05) for both groups. Since there 
was an increase in arterial elasticity in both the training and control groups, the 
changes cannot be attributed to the resistance training. A similar study which also
48
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examined the effects of 12 weeks of leg resistance training on arterial function, 
found no change in arterial elasticity with training65. This study only examined 
men, had a relatively small sample size (n = 11), and did not have a control group 
for comparison. Since the subjects only exercised twice per week at 60% of 1-RM, 
the resistance training program may not have been strenuous enough to elicit a 
modification in the vasculature. Cortez-Cooper et al. examined arterial stiffness 
after 11 weeks of high-intensity resistance training in young women 19. The first 4 
weeks the subjects performed three sets of ten repetitions until failure, followed by 
another 4 weeks of three sets of five repetitions. In the last three weeks of the 
intervention, upper and lower body exercises were paired and incorporated using six 
sets of five repetitions in which the weights were increased for four sets then 
decreased for two sets. They found an increase in large arterial stiffness in the 
training group compared to that of the control group. This study did not agree with 
our findings, which could possibly be due to a more strenuous training program and 
the inclusion of upper body resistance exercises. Recreational resistance training 
program or a therapy program is usually not as strenuous, which might explain some 
of the variation seen in arterial elasticity with resistance training. This suggests that 
there may be a dose response issue that needs to be further examined, and that 
moderate intensity resistance training may not produce the negative effects on the 
arteries, which is often observed with high intensity resistance training.
Kawano et al. examined the effects of moderate resistance training as well as 
the combined resistance and endurance training on large arterial elasticity 45. 
Thirty-nine healthy men were assigned to either the moderate-intensity training
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(MODE) group, the combined resistance and endurance training (COMBO) group 
or the sedentary control (CONTROL) group. The subjects trained 3 times per week 
for 4 months followed by another 4 months of detraining. The COMBO group 
completed three sets of 8-12 repetitions at 80% of 1-RM and the MODE group 
completed three sets of 14-16 repetitions at 50% of 1-RM. The COMBO group 
performed a cycle exercise at 60% of the maximal heart rate for a duration of 30 
minutes, immediately after completing the resistance training protocol. This study 
found a significant decrease in arterial compliance of approximately 20% after 
MODE training, contrary to our results, and no significant changes were observed in 
the COMBO or CONTROL groups. The study further showed that large arterial 
compliance returned to baseline following the detraining period. Small arterial 
elasticity did not change in any of the groups, which is in agreement with our study. 
This study concluded that simultaneously performed endurance exercise and 
resistance exercise could prevent the stiffening effect of the arteries that is often 
seen with resistance training alone.
Our results are not in agreement with Miyachi et al. who showed that arterial 
elasticity decreased after 2 months of resistance training75. The subjects were non- 
obese men aged 20-38 years old and trained 3 days per week, who completed 3 sets 
of 8-12 reps at 80% of 1-RM, which is very similar to our study. However, this 
study resistance trained both lower and upper body, compared to our focus on lower 
body exercises.
For our study, the relative changes in Cl were 9% and 13% for the training 
group and the control group, respectively. The changes observed in Cl are not
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believed to be due to measurement error as the coefficients of variation were small. 
The increase in large arterial elasticity observed in the current study from pre to post 
in both groups, could possible be due to increased physical activity with spring 
approaching. Perhaps the subjects became more active outside the training study, 
although they were instructed to continue their normal daily activity. Physical 
activity outside the study was not controlled, which is a limitation, and it is possible 
that if both the training group and the control group engaged in more endurance type 
of activities, this could have had a positive effect on the elasticity of the arteries. 
Recreational physical activity has been associated with increased arterial elasticity 
38,102, however, it is important to note that other studies have not found this 
relationship 10°.
Our study found no significant changes in small arterial elasticity (p > 0.05), 
which is in agreement with two other studies that found no differences in small 
arterial elasticity between sedentary and resistance trained m en74 and women 19. It 
has been suggested that the decrease in arterial elasticity is more rapid in the large 
arteries compared to the small40, and that may explain why we did not observe any 
changes in small arterial elasticity in just 12 weeks of training. Perhaps a training 
program of longer duration is necessary to detect any changes in the peripheral 
arteries.
Estrogen Status and Arterial Elasticity
Although the current study only examined premenopausal women, natural
menopause in healthy women has been shown to decrease arterial elasticity 123, 
whereas hormone replacement therapy seems to attenuate this process in
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'l'X  1 ( \  01postmenopausal women ’ ’ . Previous studies have documented that healthy 
premenopausal women have greater arterial elasticity compared to their
191postmenopausal peers . The exact mechanism in which menopause exerts its 
effect on the cardiovascular system remains unclear. In animal studies, it has been 
hypothesized that estrogen has a vasodilatory effect on the vasculature, resulting in
1 98greater elasticity of the arteries . Further, studies have shown that 
postmenopausal women who take hormone replacement therapy have more elastic 
arteries compared to postmenopausal women who do not take any hormone 
replacement therapy, further suggesting the beneficial effect of estrogen 
supplementation. Another limitation of this study is that hormone supplementation, 
menopausal status and physical activity was based on self-report, which often are 
subject to recall bias and misclassification. Studies have reported that different 
phases of the menstrual cycle can have an impact on arterial elasticity39, whereas 
others have not found this relationship 127My study did not examine baseline and 
post-test arterial elasticity in the same phase of the subject’s menstrual cycle, which 
could pose as a limitation of this study.
The current study only examined premenopausal women who were not 
taking any hormonal contraceptives, so the slight increase in large arterial elasticity 
in both the training group (9%) and the control group (13%), could not be attributed 
to the intervention or hormone supplementation. It is possible that natural estrogen 
levels in the subjects had a protective effect that resulted in a greater increase in
Q 7Slarge arterial elasticity, contrary to similar studies completed in men ’ .
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C-Reactive Protein
The current study examined the inflammatory marker C-reactive protein
(CRP), which is a marker of inflammation and is considered a risk factor for 
cardiovascular disease n . At baseline, there were no differences in CRP levels 
between the training group and the control group (p > 0.05), and there were no 
significant (p > 0.05) differences after the training period for any of the groups.
This study revealed a weak and non-significant (p > 0.05) relationship between CRP 
levels and large and small arterial elasticity both at baseline and after the training 
period. This is not in agreement with other studies, which found that raised 
concentrations of CRP are associated with a decreased arterial elasticity or increased 
stiffness of the arteries in healthy individuals2I’70,131 and in hypertensives 47,66.
Why our data do not support the studies mentioned above is unclear. It could 
possibly be due to technical error during the arterial elasticity measurement, the 
subjects not complying with the proposed fasting and resting assumptions or too 
small of a sample size to detect a significant relationship.
Further analyses showed that after twelve weeks of resistance training there 
were no significant changes in CRP concentrations in any of the groups (p > 0.05). 
However, CRP levels had a non-significant increase of 83.9% for the training group 
and 9% for the control group. This large percent change was in part due to one 
subjects’ increase in CRP levels from pre to post, but it is important to note that this 
subject was still within the normal ranges for an adult. Just one other study was 
found that examined CRP before and after resistance training in premenopausal 
women. Cortez-Cooper at al. found no changes in CRP after 11 weeks of resistance 
training, which is in agreement with our study 19. This study used a high-intensity
53
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
strength training program, which was designed for the subjects to perform each set 
of ten repetitions until failure. Most of the other studies are cross-sectional, 
examined men and focused on different inflammatory markers.
Rail et al. also examined the effects of 12 weeks of resistance training on 
various cytokines, including inflammatory markers such as TNF-a, IL-1, IL-2, and 
IL-6 96. The resistance trained male subjects performed 8 repetitions (80% 1-RM),
3 sets, twice per week for 12 weeks. They reported that high-intensity resistance 
training did not affect the concentrations of inflammatory markers, which is in 
accordance with our study, although we measured a different marker.
Petridou et al. had their subjects perform 3 sets of 10 resistance exercises 
with 10-12 repetitions at 70-75% of 1-RM in a circuit training fashion87. This study 
examined serum concentrations of vascular cell adhesion molecule-1 (VCAM-1), 
intercellular cell adhesion molecule-1 (ICAM-1), E-selectin, P-selectin and L- 
selectin. No changes were observed in the concentrations of these cell adhesive 
molecules, suggesting no negative effect on immune function. This study examined 
a small sample of young men, and did not investigate CRP.
For this study there was concern regarding the lapse in time between the last 
1-RM and the blood draw, and whether or not this was a biological error in regards 
to the results of the CRP concentrations Several cross-sectional studies have 
examined various inflammatory markers that have shown minor changes in plasma 
cytokine concentrations41, whereas others have shown that post-exercise changes in 
cytokines do occur 72-144 hours after high-intensity resistance exercise, but when 
compared to strenuous endurance exercise, they are generally of smaller magnitude
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and occur at a later time after the termination of exercise 104. With these conflicting 
results, it is difficult to predict if it would have made a difference if the subjects had 
their last blood draw a few days after completing their last 1-RM.
Muscular Strength
Muscular strength was assessed by 1-RM (kg) for seven exercises targeting
the lower body. The seven exercises tested were hip flexion, hip extension, hip 
adduction, hip abduction, leg press, calf raises, and shin strength. There were no 
significant (p > 0.05) differences in strength between the groups at baseline. From 
baseline, the training group significantly (p < 0.05) increased 1-RM strength for hip 
flexion, hip abduction, leg press, and calf raises at week 12 compared to the control 
group. There were significant (p > 0.05) increases in strength from baseline for hip 
extension, hip adduction, and shin exercise in both the training group and the 
control group.
The training group had a significantly (p <0.01) greater percent change for 
the seven exercises compared to the control group. The greater percent increase in 
hip flexion, hip extension, hip adduction and hip abduction compared to the control 
group were 66%, 38%, 40%, and 42%, respectively. For the remaining exercises 
(leg press, calf raises, and shin exercise), the training group had the following 
greater increases in strength: 22%, 49%, and 49%, respectively, compared to the 
control group.
Prabhakaran et al. had premenopausal women participate in resistance 
training sessions (80% 1-RM), three days a week for 14 weeks 90. The control 
group did not take part in any structured exercise during the training period. The
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training comprised of loading the major muscle groups (legs, arms, trunk, and lower 
back). Subjects performed two sets of eight repetitions and went to exhaustion on 
the third set. Fourteen weeks of resistance training resulted in a total increase in 
strength for the eight exercises by 27%, whereas the control group either remained 
unchanged or significantly decreased. This study has similarities to the current 
study, however, the subjects in our study were on average a little older, and did not 
exercise to exhaustion in the third set.
Another study by Cortez-Cooper et al. examined high-intensity and power 
resistance training in healthy young women (mean age 29 years)19. The training 
study lasted 11 weeks using a light-day/heavy-day periodized approach. The 
specific exercises included bench, press, overhead press, weight-assisted parallel bar 
dip, dumbbell crossover pull, dumbbell rowing motion, deadlift, medicine ball drills 
latissimus dorsi pulldown, dumbbell curls, and abdominal exercises. The first 4 
weeks the subjects performed three sets of ten repetitions to failure. The subsequent
4 weeks, three sets of five repetitions were performed, and the last three weeks of 
the intervention consisted of paired upper and lower body exercises using six sets of
5 repetitions which the weights increased for four sets then decreased for two sets. 
The training group increased their maximal muscle strength by 20% for bench press 
and 13% in squat. However, contrary to our study, this study did not have their 
control group perform 1-RM exercises for comparison.
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CHAPTER V 
CONCLUSIONS
The purpose of this study was to examine the effects of twelve weeks of 
resistance training on large (Cl) and small (C2) arterial elasticity in premenopausal 
healthy women, and in a group of healthy controls. The secondary purpose was to 
examine the relationship between the inflammatory marker C-Reactive Protein 
(CRP), and arterial elasticity in premenopausal healthy women, and in a group of 
healthy controls.
The following research questions were examined: 1) Will twelve weeks of 
lower leg resistance training change arterial elasticity and levels of CRP in 
premenopausal women? 2) What is the relationship between CRP and arterial 
elasticity in premenopausal women?
Research Hypothesis 1. Twelve weeks of lower leg resistance training will 
change arterial elasticity.
No, the results of this study did not support this hypothesis. Large arterial 
elasticity significantly increased (p < 0.05) from pre to post for both groups, thus the 
change cannot be attributed to the treatment. The training group had a 9% increase, 
and the control group had a 13% increase (p > 0.05). There were no significant 
changes in small arterial elasticity for any of the groups (p > 0.05). Non-significant 
increases (p > 0.05) were 5.8% for the training group and 11.5% in the control 
group. Furthermore, there were no significant changes in CRP levels after the 
twelve week training protocol (p > 0.05).
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Research Hypothesis 2. It is expected that there will be a negative relationship 
between C-Reactive Protein concentrations and arterial elasticity measures.
Yes, this study does support this hypothesis; however the relationships were 
weak and non-significant (p > 0.05). There was a weak correlation between CRP 
and Cl (r = -0.163, p = 0.373), and C2 (r = -0.183, p = 0.317).
Clinical Significance
The current study explored arterial elasticity after 12 weeks of lower body
exercises, and found an increase in large arterial elasticity for both the training 
group and the control group, but these results can not be attributed to the resistance 
training alone. This might suggest that resistance training alone may not have the 
same effect on arterial elasticity in women as often observed in men. Further, if this 
is correct, this could be a good approach for postmenopausal women who want to 
preserve bone mass and muscle mass and at the same time keep their cardiovascular 
system healthy. More research is needed examining whole body resistance training 
and arterial elasticity in postmenopausal women.
Future Research Directions
Most of the arterial compliance research until now has primarily focused on
men, with women receiving very little attention. In the future it is important to 
examine arterial elasticity in women and the various effects of training. With 
advancing age and natural menopause, there seem to be a decrease in arterial 
elasticity with the loss of estrogen. Future research should focus on: 1) exercise 
interventions that will explore arterial elasticity in both premenopausal and
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postmenopausal women, and 2) the effect of a combination of endurance and 
resistance training on arterial elasticity over time in both men and women. More 
specifically; future studies should monitor physical activity outside the study, 
measure estrogen levels and their association with arterial elasticity, incorporate 
whole body resistance training, and explore a potential dose-response relationship in 
terms of intensity and duration of the intervention. Examinations like this may play 
an important role in determining what strategies to explore to achieve the most 
beneficial effects on all aspects of health. With the limited data available on the 
combination approach, we may speculate that the vasculature will improve with 
endurance training and possibly prevent future cardiovascular events. Concurrently, 
the resistance training aspect will enhance bone mass and muscular strength, 
combined giving these subjects more independence and a greater quality of life.
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Weight Training Study
The Department of Health and Exercise 
Science at the University of Oklahoma, 
Norman is performing a study to examine 
the effects of 16 weeks of resistance 
training on blood vessel function in adult
women.
Pre-menopausal women between the ages 
of 18 years and 40 years, non-pregnant 
and free of cardiovascular disease are 
needed as volunteers to complete this 
study. You will receive information 
regarding your cardiovascular function, 
bone density, body composition, and 
muscle strength.
Please contact Anette S. Fjeldstad 
408-6642 (cell), or 
e-mail: Anette.S.Fjeldstad-l@ou.edu 
for more information.
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INFORMED CONSENT 
TO PARTICIPATE IN A RESEARCH STUDY
PROJECT TITLE:
PRINCIPAL INVESTIGATOR: 
CONTACT INFORMATION:
CO-Frinciple Investigator: 
Contact Information:
Co-Investigator: 
Contact Information:
EFFECTS OF RESISTANCE TRAINING O N  ARTERIAL 
ELASTICITY AND C-REACTIVE PROTEIN IN  
PREMENOPAUSAL W OMEN
Dr. Debra Bemben 
Debra Bemben, PhD
Department of Health and Exercise Scien ce
1401 Asp Avenue, Room 119, Norman, OK 73019
Telephone (405) 325-2709
Email: dbemben@ ou.edu
Anette S. Fjeldstad, PhD Candidate
Department of Health and Exercise S cien ce
1401 Asp Avenue, Room 112, Norman, OK 73019
Telephone (405) 408-4&42
Email: Anette,S.Fjeldstad-1@ou.edu
Dr. Michael Bemben
Department of Health and  Exercise S c ien ce  
1401 Asp Avenue, Room 120, Norman, OK 73019 
Telephone (405) 325-2717 
Email: mabemben@ ou.edu
You a r e  b e in g  a s k e d  to  v o lu n te e r  for a  r e s e a rc h  study . This s tu d y  is b e in g  c o n d u c t e d  a t  th e  
University o f  O k la h o m a , N o rm an  C am p u s . You w e re  s e le c te d  a s  a  p o ss ib le  p a r tic ip a n t 
b e c a u s e  y o u  tit th e  inclusion criteria . P le a se  r e a d  this form  a n d  ask  a r ty  q u e stio n s  th a t  you 
m a y  h a v e  b e fo re  a g r e e in g  to  ta k e  p a r t  in this study.
Purpose of the Research Study
The p u rp o s e  o f this s tu d y  is to  e x a m in e  th e  e ffe c ts  o f tw e lv e  w e e k s  o f re s is ta n c e  tra in in g  on  
a r te r ia l e lastic ity , w h ich  is a n  in d ic a to r  o f b io d d  ve sse l fu n c tio n , in p r e m e n o p a u s a l  w o m e n . 
The s e c o n d a ry  p u rp o s e  is to  e x a m in e  th e  re la tio n sh ip  b e tw e e n  m e a s u re s  o f a rte ria l elastic ity  
a n d  a n  in d ic a to r  o f in flam m atio n  (C -rea c tiv e  p ro te in ) fo u n d  in th e  b lo o d . R esis tan ce  
tra in ing  h a s  sh o w n  to  h a v e  c a rd io v a sc u la r  b e n efits , b u t  th e  sp ec ific  e f f e c ts  o f this ty p e  of 
e x e rc ise  o n  b lo o d  vessel fun c tio n  a r e  n o t c le a r . It is im p o r tan t to  e x a m in e  th e  e f fe c ts  of 
e x e rc ise  o n  b lo o d  vessel fun c tio n  b e c a u s e  th e  loss o f a rte ria l e la stic ity  w ith  a g e  is a s s o c ia te d  
w ith c a rd io v a s c u la r  d ise a se s . P a rtic ip an ts  m ust b e  b e tw e e n  th e  a g e s  18 a n d  50 y ears , b e  
p re m e n o p a u s a l ,  n o t  p re g n a n t ,  a n d  n o t  tak in g  h o rm o n a l birth c o n tro l o r b lo o d  p ressu re  
m e d ic in e .
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Exclusion C riteria
1) W o m en  w h o  a re  p r e g n a n t  2} w o m e n  n o t in th e  a g e  g ro u p  18-50 y e a rs  o f a g e ,  3} m a le s , 
4) th o s e  w ith a  history o f c a rd io v a sc u la r  d is e a s e ,  c o ro n a ry  h e a r t  d is e a s e ,  o r p e r ip h e ra l 
a rte ria l d is e a s e , 5) c u rre n t sm okers, 6 )  w o m e n  w h o  a r e  p o s tm e n o p a u s a l ,  a n d  7) th o s e  w h o  
ta k e  h o rm o n a l birth co n tro l or b lo o d  p re ssu re  m e d ic in e .
Procedures
If y ou  a g r e e  to  b e  in this s tudy , you.will b e  a s k e d  to  d o  th e  following things:
a .  You will b e  re q u ire d  to  r e a d  a n d  sign  d n  in fo rm ed  c o n s e n t  fo rm  b e f o r e  th e  te stin g  ta k e s  
p la c e .
b .  You will fill o u t  a  m en stru a l history q u e s tio n n a ire  p rov id ing  in fo rm a tio n  a b o u t  c u rre n t 
m en stru a l s ta tu s, a n d  p a s t  m e n stru a l history.
c .  You will fill o u t  a  h e a l th  s ta tu s  q u e s tio n n a ire  p rov id ing  in fo rm ation  a b o u t  y o u r m e d ic a l  
history a n d  h e a l th - re la te d  b e h av io rs .
d . B lood vessel fu n c tio n  m e a s u re m e n ts  (Pulse C o n to u r  Analysis) will b e  o b ta in e d  in th e  
m o rn ing  follow ing a n  o v e rn ig h t fa s t o f  a t  le a s t  e ig h t hours, a n d  b e f o r e  p a r t ic ip a tin g  in 
a n y  s tren u o u s  p h y s ica l activ ity . A fter res ting  for 10 m in u tes  o n  a  th e r a p y  ta b le ,  b lo o d  
vessel fu n c tio n  will b e  o b ta in e d  using  th e  H D I/P u isew aveT“ C R-2000 C a r d io v a s c u la r  
Profiling System  (H ypertension  D iagnostic , Inc., E a g a n , M in n eso ta , USA). An a u to m a tic  
b lo o d  p re s su re  c u ff will b e  w r a p p e d  a ro u n d  m y u p p e r  left a rm , a n d  a  rigid p la s tic  wrist 
stabilizer to  m inim ize m o v e m e n t  o f th e  righ t wrist will b e  u s e d  d u rin g  th e  b lo o d  vessel 
m e a s u re m e n t.  While lying o n  th e  th e ra p y  ta b le ,  a  s te e l a n a ly z e r  will b e  p l a c e d  o n  th e  
p u lse  o f th e  right wrist. M e a s u re m e n t will b e  o b ta in e d  a n d  a v e r a g e d  o v e r  th re e  
c o n s e c u tiv e  3 0 -s e c o n d  trials. In a d d itio n  to  th e  b lo o d  vesse l m e a s u re m e n ts ,  h e ig h t a n d  
w e ig h t will b e  m e a s u re d  a n d  r e c o r d e d .  This is a  n o n in v asiv e  m e a s u re  o f b lo o d  vessel 
fu n c tio n , a n d  req u ires  th a t  you lie still du ring  th e  m e a su re m e n ts .
e . A b o n e  s c a n  will b e  p e rfo rm e d  b y  D ual Energy X-Ray A b so rp tio m e try  (DXA) a t  th e  B one 
D ensity L ab o ra to ry  in th e  D e p a r tm e n t o f H ealth  a n d  Exercise S c ie n c e .  This te s t will 
in c lu d e  tw o  s c a n s  p e rfo rm e d  a t  b a se lin e  ( th e  initial session), a n d  a t  12 w e e k s  ( th e  e n d  of 
th e  tra in ing  p ro g ram ). This te s t is n o n in v asiv e  a n d  only  req u ire s  t h a t  y o u  lie still for th e  te s t 
to  b e  c o m p le te d .  Your to ta l  b o d y  will b e  m e a s u re d  for b o n e  m in e ra l c o n te n t ,  a n d  
p e r c e n t  b o d y  fa f will b e  d e te rm in e d . This r e s e a rc h  s tu d y  invo lves e x p o su re  fo  r a d ia tio n  
from  tw o  DXA s c a n s , w h ich  is a  ty p e  o f x-ray  p ro c e d u re .  M o re  d e ta i l  a b o u t  this risk is 
d e s c r ib e d  b e lo w  In th e  risks a n d  b e n e f its  s ec tio n .
f. A re s tin g  b lo o d  s a m p le  o f a b o u t  fiml ( a b o u t  1.5 te a s p o o n s )  will b e  ta k e n  from  th e  inside 
o f  y o u r e lb o w  (v en ip u n c tu re ) b y  q u a lified  p e rso n n e l a t  The University o f O k la h o m a  a t  
b a se lin e  (initial session) a n d  a t  12 w e ek s  (th e  e n d  of t h e  tra in ing  p ro g ra m ) . T hese 
s a m p le s  will b© u s e d  fa  m e a s u re  a h  in flam m a tio n  s u b s ta n c e  c a l l e d  O r e a c t l v e  p ro te in .
The s a fe ty  o f t h e  s u b je c t  is o f o u tm o s t im p o r ta n c e  d u rin g  th e  b lo o d  d raw s, th e re fo re  
s ta n d a r d  p re c a u t io n s  will b e  u s e d  in c lu d in g  c le a n in g  o f th e  v e n ip u n c tu re  site  w ith  
a lc o h o l, th e  u s e  o f n e w  sterile d is p o sa b le  n e ed le s /sy rin g e s  a n d  c h a n g in g  o f d is p o sa b le  
g lo v es  in b e tw e e n  su b je c ts  b y  th e  re g is te re d  n u rse /p h le b o fo m is t. The su b jec ts  d o  NOT 
h a v e  to  p a y  for this p ro c e d u re .  T he b lo o d  s a m p le  will b e  c o l l e c te d  tw ic e  a n d  u s e d  fo  
m e a s u re  C -re a c t iv e  p ro te in .
g .  M axim um  s tre n g th  te s tin g  (IRM) will b e  c o n d u c t e d  b y  t ra in e d  p e rs o n n e l a t  th e  
N e u ro m u scu la r L ab o ra to ry  in th e  D e p a r tm e n t o f H ealth  and E xercise S c ie n c e . This te s t 
will b e  p e rfo rm e d  a t  m on th ly  in tervals a n d  requ ires th a t  yo u  g iv e  m a x im u m  effort for 
e a c h  ex erc ise .
h. if you  a r e  a s s ig n e d  to  th e  co n tro l g ro u p , yo u  will m a in ta in  your n o rm a l daily  activ ities  th a t  
d o  n o t  involve re s is ta n c e  train ing .
i. If you  a re  a s s ig n e d  to  th e  re s is ta n c e  tra in ing  g ro u p , y o u  will re p o r t  to  th e  N eu ro m u scu la r
r re s is ta n c e  tra in ing
Page 2 of 4
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sessions for a b o u t  30 m inu tes  a  d a y ,  3 d a y s  a  w e e k , for a  to ta l o f 12 w e ek s . The hip 
ex e rc ise s  will consist o f 2 sets  of 8  re p e titio n s  a t  a  h ig h  intensity  (80% 1-RM) p e rfo rm e d  o n  
1 re s is ta n c e  ex e rc ise  m a c h in e  ta rg e t in g  th e  m a jo r m u sc le  g ro u p s  o f  th e  low er b o d y . The 
res t o f th e  ex erc ises  wilt consist o f 3 se ts  o f 8 re p e titio n s . The le g  p ress  e x e rc ise  will b e  
p e r fo rm e d  a t  80% 1-RM, w h e re a s  th e  tw o  a rm  ex erc ise s  a n d  th e  c a lf  a n d  shin e x e rc ise  
will b e  p e rfo rm e d  a t  a  light intensity.
Risks and Benefits of Being in the Study
The s tu d y  h a s  th e  following risks.
You u n d e r s ta n d  th a t  w h e n  perfo rm in g  a n y  of th e  req u ire m e n ts  for this p ro je c t ,  th e re  will b e  
q u a lifie d  p e rso n n e l p re s e n t a t  all tim es, b u t y o u  sh o u ld  b e  a w a r e  o f th e  following:
a .  T here  is a  possibility o f brusing  from  b lo o d  d ra w s. If sh o u ld  b e  n o te d  th a t  all b lo o d  
c o lle c tio n  p ro c e d u re s  will b e  d o n e  in a  c le a n  en v iro n m e n t by  q u a lif ie d  p e rs o n n e l (i,e„ nurse  
o r  p h le b o to m is f) . The s a fe ty  o f th e  s u b je c t  is o f u tm o s t im p o r ta n c e  d u rin g  th e  b lo o d  d ra w s, 
th e re fo re  s ta n d a r d  p re c a u t io n s  will b e  u s e d  in c lu d in g  th e  c le a n in g  o f th e  v e n ip u n c tu re  site 
w ith a lc o h o l, th e  u se  o f n e w  sterile d is p o sa b le  n e e d le s /s y rin g e s  a n d  c h a n g in g  o f d isp o sa b le  
g lo v e s  in b e tw e e n  su b jec ts  b y  th e  p h leb o to m isf.
b . This re s e a rc h  s tu d y  involves e x p o su re  to  ra d ia tio n  from  tw o  DXA s c a n s , w h ich  is a  ty p e  o f 
x -ray  p ro c e d u re .  This ra d ia tio n  p ro c e d u re  is n o t  n e c e s s a ry  for m e d ic a l  c a r e ,  a n d  is fo r 
r e s e a rc h  p u rp o s e s  only. You will re c e iv e  ra d ia tio n  e x p o su re  from  e a c h  DXA s c a n  th a t  is 
e q u iv a le n t  to  th e  ra d ia tio n  ex p o su re  A m erican s  re c e iv e  in sev e ra l d a y s  from  n a tu ra l 
b a c k g r o u n d  ra d ia tio n  f-3 0 0 m re m /y e a r)  from  s o u rc e s  s u c h  a s  ra d io a c tiv ity  in t h e  soil. Any 
risk from  this a m o u n t  o f ra d ia tio n  is to o  sm all to  b e  m e a s u re d  d irec tly . A ltough  th e  a m o u n t  of 
r a d ia tio n  e x p o su re  r e c e iv e d  in th e  s tu d y  is m inim al, it is im p o r tan t for y o u  to  b e  a w a r e  fh a i 
th e  risk tra m  ra d ia tio n  e x p o su re  is c u m u la tiv e  a v e r  a  lifetim e. If y o u  p a r t ic ip a te  in th e  
r e s e a rc h  y o u  will re c e iv e  2  DXA s c a n s  th a t  y o u  w o u ld  n o t re c e iv e  il y o u  c h o s e  n o t to  
p a r t ic ip a te ,
c .  You m a y  e x p e r ie n c e  m inor d isco m fo rt du ring  th e  m e a s u re m e n t  o f a m i b lo o d  p ressu re  d u e  
to  th e  inflation  of th e  b lo o d  p ressu re  cuff. H o w ev er, th e  tra in e d  p e rs o n n e l will m a k e  sure  th a t  
th e  b lo o d  p ressu re  cu ff is c o m p le te ly  d e f la te d  b e tw e e n  e a c h  trial.
Pregnant w om en should not b e  exp osed  to radiation. Therefore, I verify that I am  nof 
pregnant (if participant is uncertain about pregnancy, then she should not perform this test). 
Radiation safety levels for fetuses have not b een  established and therefore no additional 
exposure w hatsoever can  b e  considered safe.
I verify that I have read  and understood the above radiation Warning.
Initials:_______
The b e n e f its  to  p a rtic ip a tio n  a r e  th a t  y o u  will r e c e iv e  in fo rm ation  a b o u t  y o u r b lo o d  vessel 
fu n c tio n , b o n e  density , p e r c e n t  b o d y  fa t, a n d  m u s c le  s treng th . N o th e r a p e u t ic  v a lu e  shou ld  
b e  e x p e c t e d  from  p a r tic ip a tin g  in th e  re s e a rc h .
Com pensation
You will n o t  b e  re im b u rsed  for your tim e  a n d  p a r tic ip a tio n  in this s tudy . In c a s e  o f injury or 
illness resulting  from  this s tudy , e m e rg e n c y  m e d ic a l  t r e a tm e n t  is a v a i la b le .  H ow ever, yo u  o r 
you r in s u ra n c e  c o m p a n y  m a y b e  e x p e c t e d  to  p a y  th e  u su a l c h a r g e  for this tre a tm e n t .  The 
University of O k la h o m a  N orm an  C a m p u s  h a s  s e t  n o  fu n d s  a s id e , to  c o m p e n s a t e  yo u  in th e
e v e n t  o f injury. A P p g p V A f
a p p r o v e s .
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C onfiden tia lity
The re c o rd s  o f  fhis s tu d y  will b e  k e p t p riv a te . In p u b lish e d  repo rts , th e re  will b e  n o  inform ation  
in c lu d e d  th a t  will m a k e  it possib le  to  identify  th e  re s e a rc h  p a r tic ip a n t.  R e s e a rc h  reco rd s  will 
b e  s to re d  secu re ly . C onfiden tia lity  wilt b e  m a in ta in e d  b y  c o d in g  a ll in fo rm a tio n  with 
ind iv idual id e n tific a tio n  n u m b ers . The m a s te r  list will b e  k e p t  in a  lo c k e d  file c a b in e t  in th e  
Pi's (Dr. D e b ra  B e m b e n  a n d  Co-PI, A n e tfe  $, Fjeldstqd) o ffice . Dr. D e b ra  B e m b e n  a n d  
A n e tte S . F je ld s tad  wilt h a v e a c c e s s  to  th e  m e d ic a l  s c re e n in g  q u e s tio n n a ir e .  In a d d itio n , th e  
tw o  in v estig a to rs  will s h a r e  d a t a  c o l le c te d  d u rin g  t h e  DXA s c a n  (a  form  o f x-ray), b lo q d  
s a m p le s , a n d  dll o th e r  q u e stio n n a ires , O nly q u a lifie d  r e s e a rc h  p e rs o n n e l  a n d  University o f  
O k la h o m a  Institu tional R ev iew  B o ard  flRB) will h a v e  a c c e s s  to  d a t a b a s e  c o n ta in in g  s tu d y  
in fo rm ation . All s tu d y  d a t a  a r e  e n te r e d  in to  sta tis tica l a n a ly se s  a n d  p u b lic a tio n  re p o rts  will 
re fe r to  g ro u p  m e a n  d a t a .  N o indiv idual o r g ro u p  o th e r  th a n  th e  r e s e a r c h  te a m  will b e  g iv en  
in fo rm ation , unless sp ec ifica lly  re q u e s te d  b y  y o u . All s u b je c t- re la te d  m a te r ia ls  a n d  d a t a  will 
b e  h e ld  c o n f id e n tia l a n d  will b e  s to re d  in th e  Pi's re c o rd s  for a  p e r io d  n o t  less th a n  5 years . 
After this tim e , ali s u b je c t- r e la te d  m a te ria ls  a n d  d a t a  wilt b e  d e s tro y e d .
Voluntary Nature of the Study
P a rtic ip a tio n  in this s tu d y  is vo lun tary . Your d e c is io n  w h e th e r  o r n o t to  p a r t ic ip a te  will n o t 
result in p e n a l ty  o r loss o f b e n e f its  to  w h ich  y o u  a r e  o th e rw ise  e n title d . If y o u  d e c id e  to  
p a r t ic ip a te ,  y o u  a r e  f r e e  to  n o t a n sw e r a n y  q u e stio n  o r w ith d raw  a t  a n y  tim e  w ithou t 
a f fe c tin g  th o s e  re la tionsh ips.
Contacts and Questions:
The re sea rc h e r(s )  c o n d u c t in g  this s tu d y  c a n  b e  c o n t a c t e d  a t  Dr. D e b ra  B e m b e n  a n d  A n e tte  
S. F je ld s tad , University o f  O k la h o m a , D e p a r tm e n t o f H ea lth  a n d  Exercise S c ie n c e , 1401 Asp 
A v en u e , R o o m  109, N o rm an , OK 730V9. T e le p h o n e  (cell) (405) 408-6642, E-mail:
A netfe ,S ,f je ld s fa d - t@ o u .e d u . You a r e  e n c o u r a g e d  to  c o n t a c t  t h e  re s e a rc h e r(s )  if yo u  h a v e  
a n y  q u e stio n s .
If yo u  h a v e  a n y  q u e stio n s  a b o u t  y ou r rights a s  a  r e s e a rc h  p a r tic ip a n t,  y o u  m a y  c o n ta c t  th e  
University of O k la h o m a  -  N o rm an  C a m p u s  Institutional R ev iew  B o ard  jOU-NC IRB) a t  (405) 
325-8110 o r irb @ o u .ed u .
You will b e  given a copy of this information to keep for your records. If you are not given a 
copy of this consent form, please request one.
STATEMENT OF CONSENT
I h a v e  r e a d  th e  a b o v e  in form ation . I h a v e  a s k e d  q u estio n s  a n d  h a v e  r e c e iv e d  satisfac to ry  
an sw ers . I c o n s e n t  to  p a r t ic ip a te  in th e  study.
S ig n a tu re  of s u b je c t_______________________  D a te .
OUNCIRB-ICF 
02 i 02005
DEC 1 3 2086
APPROVED
Page 4 o f A
OU-NC IRB __________ jEXPIRES
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UNIVERSITY OF OKLAHOMA -  NORMAN CAMPUS
INSTITUTIONAL REVIEW BOARD
AUTHORIZATION TO USE or DISCLOSE 
PROTECTED HEALTH INFORMATION FOR RESEARCH
An additional Informed Consent Docum ent 
for Research Participation m ay also b e  required.
Title of Research Project:
Principal Investigator:
IRB Number:
Address:
Phone Number:
EFFECTS OF RESISTANCE TRAINING O N ARTERIAL 
ELASTICITY AND C-REACTIVE PROTEIN IN 
PREMENOPAUSAL WOMEN
Dr. Debra Bemben
1401 Asp Ave. Huston-Huffman Center, Norman, 
OK 73019
(405) 325-2709
If you d ec id e  to join this research project, University of O klahom a (OU) researchers 
m ay use or share (disclose) information ab o u t you th a t is considered  to  b e  
p ro tec ted  health information for their research. P ro tected  health  information will 
b e  ca lled  private information in this Authorization.
Private Information To Be Used or Shared. Federal law requires th a t researchers 
g e t  your permission (authorization) to use or share your private information. If you 
give permission, the researchers m ay use or share with the p eo p le  identified in this 
Authorization any private information related  to  this research  from your m edical 
records a n d  from any test results. Information, used  or shared, m ay  include all 
information relating to  any tests, procedures, surveys, or interviews as outlined in 
th e  co n sen t farm, m edical records a n d  charts, n am e, address, te lep h o n e  
num ber, d a te  of: birth, race , a n d  governm ent-issued identification num ber.
Purposes for Using or Sharing Private Information. If you give permission, the 
researchers m ay use your private infbhpatidh to  help us gain insight into how 
resistance training affects various cardiovascular param eters in p rem enopausal 
w om en. This c a n  lead  to  interventional strategies to improve cardiovascular 
function in prem enopausal women.
Other Use and Sharing oPPrivate Information. If you give permission, the 
researchers m ay also use your private information to  develop  new  procedures or 
com m ercial products. They m ay share your private information with th e  research  
sponsor, th e  OU Institutional Review Board, auditors an d  inspectors w ha ch eck  the 
research, a n d  governm ent agencies such as the Food an d  Drug Administration
APPROVED r - ........----------- }
j DEC ! 3 2006 j
^TTOTn‘TRR'w
i
i'A lT  
L......... . , . J  j
—  —  - .  — ..... EXFiRF? !
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iFDA) a n d  the D epartm ent of Health a n d  Human Services (HHSj. The researchers 
m ay  also share your private information with the o ther Principal Investigator.
Confidentiality. Although the researchers m ay report their findings in scientific journals 
or meetings, they will not identify you in their reports. The researchers will try to k eep  
your information confidential, but confidentiality is not g u a ra n te e d . Any person or 
organization receiving the information b ased  on this authorization cou ld  re-release 
th e  information to  others an d  federal law would no longer p ro tec t if.
YOU MUST UNDERSTAND THAT YOUR PROTECTED HEALTH INFORMATION MAY INCLUDE 
INFORMATION REGARDING ANY CONDITIONS CONSIDERED AS A COMMUNICABLE OR 
VENEREAL DISEASE WHICH MAY INCLUDE, BUT ARE NOT LIMITED TO, DISEASES SUCH AS 
HEPATITIS, SYPHILIS, GONORRHEA, AND HUMAN IMMUNODEFICIENCY VIRUS ALSO 
KNOWN AS ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS).
V o lu n ta ry  C h o ic e , The cho ice  to  give OU researchers permission to  use or share your 
private information for their research  is voluntary. It is com pletely  u p  to  you. No one  
c o n  feree  you to  give permission. However, you must give permission for OU 
researchers to  use or share your private health information if you w an t to  partic ipate  
in th e  research  a n d  if you revoke your authorization, you c a n  no longer partic ipate  in 
this study.
Refusing to  give permission will not affec t your ability to  g e t routine treatm en t or 
health  c a re  from OU.
Revoking Permission, if you give the OU researchers permission to  use or share, 
your private information, you h av e  a  right to  revoke your permission w henever you 
w ant. However, revoking your permission will not apply to information th a t the 
researchers h av e  already used, relied on, or shared.
End of Permission. Unless you revoke it, permission for OU researchers to use or 
share your private information for their research will continue. You m ay revoke 
your permission a t  any time by writing to:
Privacy Official 
University of O klahom a
1000 Stanton I. Young Blvd., STE 221, O klahom a City, OK 73117 
If you have  questions call: (405) 271-2511
APPROVED ,
DEC 1 3 1
OtfNC IRB
A PPROVAL
II5EC 0 6 268?] 
[ 1
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Giving Permission. By signing this form, you give OU a n d  OU's researchers led by 
Dr.Debra Bemben a n d  A netfe S. Fjeldstad, permission fo share your private 
information for the research  project called  "EFFECTS OF RESISTANCE TRAINING ON 
ARTERIAL ELASTICITY AND C-REACTIVE PROTEIN IN PREMENOPAUSAL WOMEN".
Subject Nome:
Signature of Subject D ate
or Parent if Subject is a  child
**lf signed by a  Legal Representative of the Subject, provide a  description of the  
relationship to  the Subject an d  the Authority to Act as Legal Representative:
OU m ay ask you to  p ro d u ce  ev id en ce  of your relationship.
A signed co p y  of this form must be given to the Subject or the Legal 
Representative at the time this signed form is provided fo the researcher or his 
representative.
Or
Signature of Legal Representative** D ate
APPROVED
3
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Bone D ensity Research Laboratory 
Department o f  Health and Exercise Science  
University o f Oklahoma, Norman, OK 73019-0615 
Individual’s Consent Form— Dual Energy X-Ray Absorptiometry (Lunar Prodigy)
Introduction
This is to certify that I , ____________________________ agree to volunteer as a participant for bone scans to be
performed by Dual Energy X-Ray Absorptiometry (DXA) (Lunar Prodigy) at the Bone Density Research Laboratory 
on the Nonnan Campus under the supervision of Dr. Debra A. Bemben, Certified Clinical Densitometrist.
Description
A bone scan will be performed by DXA at the Bone Density Research Laboratory by qualified and trained personnel. 
This test involves exposure to radiation from the DXA scan which is a type of x-ray procedure. The bone scans will 
not be used for diagnostic purposes. This test is non-invasive and requires only that you lie still for the test to be 
complete!. Your total body will be measured for bone mineral density and body composition. You will lay on the 
DXA table for approximately 15 minutes forthe scan.
Risks
You will be exposed to minimal radiation during the total body DXA scan, which is a type of x-ray procedure. This 
radiation exposure is not necessary for medical care, and is for research purposes only. You will receive radiation 
exposure from each DXA scan-thatIs equivalent to the radiation exposure Americans receive in several days from 
natural background radiation (about 300 mrem/year) from sources such as radioactivity in the soil. This radiation 
procedure is not necessary for medical care, and is for research purposes only. Any risk from this amount of radiation 
is too small to Ire measured directly. Altough the amount of radiation exposure received in the study is minimal, it is 
important for you to be aware that the risk from radiation exposure is cumulative over a lifetime.
Pregnant women should not be exposed to radiation. Therefore, I  verify that 1 ani not pregnant (if participant is 
uncertain about pregnancy, then she should not perform this test). Radiation safety' levels for fetuses have not been 
established and therefore no additional exposure whatsoever can be considered safe. I verify that I have read and 
understood the above radiation warning.  _______ Initials
Compensation for Injury
There will be no compensation, will be available to you from the University of Oklahoma unless you otherwise qualify 
for the University’s Health Insurance or other employee benefits. This University will provide emergency medical 
treatment in the form of fi rst aid, GPR, and contacting medical personnel. No other financial aid will be provided for 
any long-term medical problems that may occur from the bone scan.
Subject Assurances
You are free to refuse to participate in any procedure or refuse to answer any questions at any time without prejudice. 
Further more, by agreeing to have thebone scan and signing this form, you do not waive any o f  your legal rights.
I understand that Dr. Debra Bemben will answer any of my questions about the scanning procedures, my rights as a 
participant, and procedure-related injuries at any time.
Date Signature of Participant
Date Debra A. Bemben, Ph.D., Laboratory Supervisor
Date Witness
APPROVED
DEC 1 3 2006
(. OU-NC IRB__
APPROVAL
{ ■ . i  It () 
j ■ __ _
gxPWESL__
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Institutional Review Board Approval Letter
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The University o f Oklahoma
OFFICE FOR HUMAN RESEARCH PARTICIPANT PROTECTION
IRB Number: 11551 
Meeting Date: December 07, 2006 
Approval Date: December 13, 2006
D ecem ber 14. 2006
D ebra Bem ben, Ph.D.
Health & Exercise Science 
1401 A spA venue, HHC 104 
Norman, OK 73019
RE: Effects of Resistance Training on Arteria} Elasticity and C-Reactive Protein in Premenopausal Women
D ear Dr. Bemben:
The University of Oklahom a Norman Cam pus Institutional Review Board (IRB) reviewed the above-referenced research  
protocol at its regularly scheduled meeting on D ecem ber 07, 2006. It is the  IRB's judgem ent that the rights and welfare of 
the  individuals who may be asked  to participate in this study will be  respected; that the proposed research , including the 
p rocess of obtaining informed consent, will b e  conducted in a  m anner consistent with the requirem ents of 45 CFR 46, a s  
am ended; and  that the potential benefits to participants and to o thers warrant the risks participants may choose to incur,
On behalf of the IRB, I have verified that the  specific changes requested  by the convened IRB have been  m ade. Therefore, 
on behalf of the  Board, I have granted final approval for this study.
This letter docum ents approval to conduct the research  a s  described;
Priv •• R esearch  Auth 1 Dated: November 29, 2006
Survey Instrument Dated: November 29, 2006 Health S tatus questionnaire
Survey Instrument Dated; November 29, 2006 Medical HistoryfTeiephone questionnaire
Survey Instrument Dated: November 29, 2006 M enstrual History questionnaire
Survey Instrument Dated: November 29. 2006 O ne Repetition Max S heet
Survey Instrument Dated: November 29, 2006 R esistance Training Sheet
IRB Application D ated: D ecem ber 12, 2006 Revised
C onsent form - Subject Dated: D ecem ber 12, 2006 Revised
C onsent form - O ther Dated: D ecem ber 12 ,2006  DXA procedure
A dvertisem ent D ated: Decem ber 12 ,2006 Revised
Protocol Dated: D ecem ber 12, 2006 Revised - Summary of study activities
As principal investigator of this protocol, it is your responsibility fo m ake su re that this study is conducted a s  approved by 
the IRB. Any modifications to the protocol or consent form, initiated by you or by the sponsor, wifi require prior approval, 
which you may request by completing a protocol modification form.
T he approval granted expires on D ecem ber 06, 2007. Should you wish to maintain this protocol in an  active s ta tu s beyond 
that date, you will need  to provide the !RB with an  IRB Application for Continuing Review (Progress Report) summarizing 
study results to date. The IRB will request a  progress report from you approximately two months before the anniversary date  
of your current approval.
If you have questions about th e se  procedures, or need  any additional ass is tance  from the IRB, p lease  call the IRB office at 
(405) 325-8110 or send an  email to irb@ ou.edu.
Carnally, /
Lynp/Devenport, P h .D ./ A
Vice Chair, Institutional Review Board
Ltr^Prot__ B
660  Farrington Oval, Suite 316, Norman. Oklahom a 73019-3085 PHONE: {405} 325-8110 FAX: <405) 325-3373
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Appendix D.
Menstrual History, Calcium Intake, Health Status Questionnaire
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Bone Density R eseraeb  L aboi a fo ry  
D e p a itn tru t ol H ealth  anil E xercise  Science 
U niversity  oi O k lah o m a
MENSTRUAL lUNTO in QUESTIONNAIRE
Name: ......................... ........... ....................................... .. Date: ________________
W e are asking yon to give us as complete a m enstrual history as possible. A ll information you 
provide will be strictly confidential.
SECTION A: CURRENT MENSTRUA], STATUS
1. A pproxim ately how  m any menstrual periods have you had during the  past 12 m onths?
2. Circle the m onths in w hich your period occurred. This m eans from  th is tim e last year 
until tliepu 'se iit month.
IAN EBB M A R APR MAY JUNE JULY AUG SEPT OC T N O V  DEC
3. W hat is lire usual length ofxou i menstrual cycle (first day m enses to  first day next
m enses)
days. Todav is day o f  your present m u is ln i i l  cycle.
4. What w as the date o f  your last period?
5. W hen d o y o u  expect your next m enstrual p nod-'
6. What is tire length (num ber o f  days) o f your m enstrual flow  on the  average?
How m any o f  these days would yon term "heavy"
Do you experience cramps durinj m n filiation (dysm enorrhea)? II yes, how m any days 
does this last?
88
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9. J > >u take ora! contraceptives o r any other m edication that includes estrogen and/or
I g sterone? I f  no, skip to question  10.
I f  ye;;, how long have yon been taking the b irth  control pill?
W hat it i  brand nam e and dosage o f  tins oral contraceptive you are tak ing?
Has the jnll af lei led your m enstrual cycle (regularity, length and am ount o f  How, length 
o f  cycle)? if yes, indicate changes.
10. H ave you taken oral contraceptives m the past? If no, skip to SE t ITU >N H.
It yes, what was the brand nam e and I L
W hen did you start taking the pill; for how long; and w hen did you stop  taking it?
11. II you answ ered yes to 9  o r 10, did you expetietice ;t weight gain und/or a chang it 
appetite  as a result o l oral contraceptive  use? 1-1 so, please indicate am ount o f  ij lit 
gam.
12. If  you are perim enopausal, are yon experiencing m enopausal sym p to m s?  P lease list your
sym ptom s (i.e ., hot Hushes, m ood sw ings, hrtidai lies etc.)
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BONE DENSITY LABORATORY 
DEPT, OF HEALTH AND SPORT SCIENCES UNIVERSITY OF OKLAHOMA
CALCIUM INTAKE ESTIMATION
N A M E:    _  TODAY'S PATE:
Complete this form (where indicate# l»  repnsstal: your dietary n t i k e j b  the jwst year.
IEA TU IIS1006;
 __________ ___________  EVERY W g R  EVERY PAY
T*ity 
f o j te  UK
onfi#
Sente
4 ftm « K
"*#
I M T i p fu n n f  size w riter*#
Kr*4a(jlWt*k
write ia*
W 1
ISO C tiitit ftxxi Of sj»fc34 t m
ISO Cfcaaesaffliw: IM.mp
ISO American decse liSkx •
ISO CMttge dneoe * « P
250 Rkoaatfeese I K
ISO Bliie«l*e«e % cop
2 » Marumi dbecjc (except entai cteesej {admits 
ebeM», Satis*, raoosjr! 1», mt4 to fiwtji t Ol
m ButMnjtBk I cap
300 Y tp ii. HaWKed or plaia 1 cap
4il) Fits! f  E«d Mil tsJute 12 oz
165 foaijfo fflM k 1 pacta
339 £***91 • t cap
m C b a l t e  milk 1 CUp
m Mtoueni m4 eteese, ctetss iouftlc> lii»saa, 
^urdic. caiitK'litjni, pirjji
IlSTO*®
im Cttafasffupertbowdet wSthraifk I cup
u s Atawrts 10 cap
ISO Bwsepfi (aap
85 8«« jKem, Jfiinesh '/s CUJI
1(9 IW W ktaw 1 cap
m r%s StfaW
m SoBopni potatoes I *»p
m S o jh w 1 cap
139 Tofu Hraip *
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[fatly
j X)pl< us*
j on #
Sfiftrt
lo$k.v *t*c
onftf
Fw4Tjft *e«*gsi*§ writ* toO •«*»*»*»
4#rv4-K*4/*i:»^***
! 30 0 A wW*e orwltofc {ran l i f e
m Witne M
i t MNOXta. hfeeak, eant&toKt 1 racdnm
40 Rssfls, fewj •%
22S EsiMcMaffia 1
139 fttsl M  t*s*s#fc*stp| ®r fcanttsto- 1 ’ [
lt« M i t b  a* fc*wr iwufts ' i
its O mhkO lisii *nd mem ' 1 O f
. m SMfck. ceokcd 4 sac '
m Owntd salmon with tone* Ho*>
208 M a t t ,  snreto. ttarjing; I I I#
toe FmJjesiclt 1 •
! i t s CSSlMipK f i f e
! 17$ Its ut'M't ot ice railk leap
toe sikhe»itt &Mp
208 Fteiea 1 top
Please ymi take bclcw, iridading (he
brand name and n m l  t* i l-
},   — .- — ■*—   —   — — —
2. : _ _ _ —     -------------
3- --— -------------------,, — — .----- — --------------------- —
4.------------ —----------    —------------ - ------
5. - ----
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Bom Density Laboratory 
OU Department o f Health and Sport Sciences 
Health Status Questionnaire
Instructions Complete each question accurately. All information provided is confidential. 
(NOTE: The M ew ing codes are for office use only: RF; MCi SLA; SBP)
Part 1. Information about tire individual
3,
Ok
4 , Gender {circle one): Female Male (wo
5. Date o f  With: Age .
6. Number o f hours worked pci week: Less than 20 20-40 41-60 Over 60
( SLA) Mm*  th an 25% of t ime spent cut job (circle ail that apply)
Sitting alttel. Uftfcg«t«yinS]orfv SUrMEof Waiting Dwrng 
Part 2. Medical history
7. (ftJFj Circle any who died o f  heart attack before age SO:
y*ifr»y MoU&ef Sbicf Ofsursdp-atfii
8. Date of: Last medical physical exam: Last physical fkuess lest: ______
VtM
9. Circle operations you have had:
EytS (SLA) JcwlfSlA)Back (SLA) 
Vm§ m
Heart (MQ 
Hernia (SLA)
Kidaey (SLA) 
Lm®(SU)
Meek (SLA)
10. Mease circie any offlte following fw w bkh yew Lave been diagnosed or treated by a  physician or health 
professional:
Alcoholism (SBP) 
Anemia, sickle cell (SEP) 
Anenria, other (SEP) . 
AaAm* {SEP)
Back strain (SLA) 
Bleeding trait (S » )
chronic 0SBP) 
Cancer <S£r>
CinhOSiS. livef (MQ
Concussion (MC) 
Congenita! defect (SEP)
Diabetes (SEP)
Epilepsy (SEP)
Eye problems (SLA)
Gout (SLA)
Wearing loss (SLA)
Heart proMem* (SLA)
High blood pressure (RE) 
Hypoglycemia (SEE)
<* .,ae~?.a, .tSjfpCf&ptQCiJl** t*A»/
Uectfom mononucleosis (MC>
ness (SKT)
Week M i  (SLA) 
©beatydtP)
IwaCOIMa (WL)
Rheumatoid arthritis (SLA) 
Strobe (MC) 
IhyroMpmWempEf) 
Ulcer (SEP)
Other
92
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Blood thinner (MQ 
Diabttic pilIjSBtt
Digitalis <MCJ 
Diuretic (MC)
Asthma
Epilepsy medieatiion tSff) Nftragtycmn (MC)
Hart-ehyAni medication (HC) Surogtn
High-Wood-prcssurc medfciilios (MC) thyroid 
JnSf»Sta|MQ
Oiler______________ _ _
t l  Any o f  these health symptoms that occurs fa tjw stiy  is the basis: for mcsfeal attention- Orcfotfw number 
Mfcatittg t»W Often you have each of t)»e foiswfag;
I ** IVactteally never
a, Gough up Mood#K) 
1 2  5 4 5
b, Abdominal pain <MQ 
I 2 3 4 $
c, Low bade jakpM)
I 2  J 4 5
Part 3 . Mealth-related M a n o r
^ F a ir ly  often 5 = Very ofi™
d  UgftffaHMC)
1 2 3 4 5. 
c. Att»«r sbsBlfcfipaia(W3i 
1 2 3 4 5 
t  atejatafltQIUQ 
1 2 3 4 5
g. SwotfettJoinefMC!
I 2 3 4 5
b. Feel feint (MQ 
1 2 3 4 5
1. DtRfeCtt'iMQ 
I 2 3 4 S
j. BreaiUtewithsBgbtrxwite#4(2 
1 2 3 4 5
13. (RF) D© you now smoke? Yes No
14. I f  you ant a smoker, indicate i»»»feer smoked per day:
Cigarettes; 40 or mete 20-39 10-19 1-9
Cigars or pipes only: 5 *  more: or any it»bafc4 La* t ta i  5, none Unfed
15. Weight now: to. O daw ariM t Ms. A ge21;______ fc.
16. Tliinkiag about the tfctag*, you do at work, howarcttk) you rate yourself a s to ihe a*ttotwt «f^tys»fai»ctJvily you 
gtst com pared with ethers o f  your age and sex?
1, Much wore active
2. Somewhat marc active
3. About the same
4. Somewhat I n  active
5. M«sh fa s  acti ve
6. Not applicable
17. Now, thinking about the M ags you do etrtsii; of wo A, how would you rate yourself as to die amount of 
physical activity you geiecwtpMsd with otters o f your age aad sex?
i. Much wore active
2. Somewhat m arc active
3. About the san e
4. Somewhat t e s  active
5. Much less active
6. ^  applicable
18. J> q y o u reg u la% ettp ig ew siiw o B S « ere i» erh a« l^ iy s iea ffab tsrt
1. Yes (answer question #  19) 2. Ho (stop)
19. Do you exercise or fator at te s t  three times a week?
L  Yes 2 . No
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Appendix E.
Weekly Training Log, 1-RM Training Log
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Resistance Training Sheet
Name:    Waak: 1,
Monday Wednesday [ Friday |
Record Actual Reps Completed Record Actual Reps Completed [ Record Actual Reps Co
Hip Flexion
Load: Set 1 Set 2 . Set 1 Set 2 S e n Set 2
. 1 V jGoal Reps: 8
Hip Extension
Load: Set1 Set 2 i l l Set 1 Set 2 Set1 Set 2
" 1 mGoal Reps: 8
Hip Abduction
Load: Set 1 s e ta Set 1 Set 2 Set 1 Set 2 ’W
~ iGoa! 
Reps: 8
Hip Adduction
Load: Set 1 Set 2 • I Set1 Set 2 S e n Set 2
I ' f 3 |
M
Goal 
Reps: 8 — j
Leg Press
Load: Set 1 Set 2 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3
Goal 
Reps: 8
Bicep Curl
Load:
SelfSetect
S e n Set 2 SetS Set1 Set 2 Set 3 Set 1 Set 2 Set 3
Goal 
Reps: 8
Tricep
Extension
Load: 
Self Select
Set 1 Set 2 S et3 S e ll Set 2 Set 3 Set 1 Set 2 Set 3
Goal 
Reps: 8
Shin
Load: Set 1 Set 2 Set 3 Set1 Set 2 Set 3 Set 1 Set 2 Set 3
Goal 
Reps: 8
Caif
Load: s e t 1 Set 2 S et3 S e n Set 2 Set 3 Set1 Set 2 Set 3
Goal 
Reps: 8
Comments:
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Name:
One Repetition Max Sheet
_______________________  Week: 1,
Warm up Max Load x % Max = New Work Load
Hip Flexion 
(right)
0.8 0
Hip Extension 
(right)
0.8 0
Hip Abduction 
(right)
0.8 0
Hip Adduction 
(right)
0.8 0
Leg Press
0.8 0
Shin
0.8 0
Calf
0.8 0
Comments:
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Appendix F.
DXA Scan Report
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Bone Density Laboratory
Dept. rtf M wltiiH  S pert Sd«*c*ss 
Univetstty ptOIMMmMtr Norman, OK. 73© i»
l / M n
t w v m *  Si I f t a r ,
jM .ussn 
ftmak m m t
Pvtfo* 10- 
RiytftiMH
MrymS;
VR0»
06,'IWMOS S 13 30 AM (8.S6, 
Hjh4#X6 *M /rt*M <«,«K
f A
an 40 m
H* »*■“*<$
t
iMP
#*8w»s
awrmmmi
m a d
P m m C &i'i
s m^r
t’*ur9e
M s H.M2
WfcM 1 139 - *
SfeNw i m
ret* \ . Y t e I •: i * 113 J J
mm BMP
€h&n®* vs
a**#* m
sowiaes «i.Sfei.3 uuMf» )£
i. J 3 » |*
. j*> ■ I «**rKf*i m »M|W *?****##* j» um *$% m#*;
UAW H*H"’
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Appendix G.
PCA Profile Report
99
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
HDllPulseWave™ CR-2000
Research Cardiovascular Profile Report
Research Subject ID: 
Protocol 1743 
Research Subject Name: 
DOE, JOHN M
Date: 23 SEPT 1999
Time: 14:35
Age: 34 years
Gender: Male 
Height: 71 in
Weight: 189 lbs. 
BSArea: 2.06 sq. meters 
Body Mass Index: 26.4
PARAMETER RESEARCH SUBJECT VALUE
SYSTOLIC BLOOD PRESSURE (mmHg) 136
DIASTOLIC BLOOD PRESSURE (mmHg) 79
MEAN ARTERIAL BLOOD PRESSURE (mmHg) 102
PULSE PRESSURE (mmHg) 57.
PULSE RATE (beats/min) 72
ESTIMATED CARDIAC EJECTION TIME (msec) 293
ESTIMATED STROKE VOLUME (ml/beat) 87
ESTIMATED STROKE VOLUME INDEX (ml/beat/m2) 42
ESTIMATED CARDIAC OUTPUT (L/min) 6.3
ESTIMATED CARDIAC INDEX (L/min/m2) 3.1
LARGE ARTERY ELASTICITY INDEX (mi/mmHg x 10) 
(Capacitive Arterial Compliance)
14.9
SMALL ARTERY ELASTICITY INDEX (ml/mmHg x 100) 
(Oscillatory or Reflective Arterial Compliance)
11.1
SYSTEMIC VASCULAR RESISTANCE (dyne.sec.crn5) 1226
TOTAL VASCULAR IMPEDANCE (dyne.sec.crn5) 111
©Copyright 1999, HYPERTENSION DIAGNOSTICS inc.™ -  All Rights Reserved. 
Eagan. MN 55121 +1-651-687-9999 Toll-Free; 1 -888-Pu/se Wave (785-7392)
Form: 00017-001 (Rev. A / 08.Oct.99) T or Research Purposes Only"
100
Average Blood Pressure Waveform
.150
100
50
1.50 Time (secs.)
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Appendix H.
CRP Elisa Instructions
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CRP ELISA
This kit is designed for the determination of C-Reactive Protein in serum, 
plasma, stool and urine.
For R esearch Use Only. Not For Use In Diagnostic Procedures.
Catalog Number: 30-971 Os
Size: 98 Wells
Version: 27.09.2005 -  ALPCO 12/19/05
28 Keewuydin Drive Unit G * Salem, NH 03079 
Plume: (800) 592-5726 *  Fax: (603) 898-8854 
www.a1pco.cam ‘ .Email: webMalpco.com
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1, Intended use
This assay is a sandwich Enzyme Immuno Assay intended for the 
quantitative determination of C-reactive Protein in plasma, serum, stool 
and urine. For research use only. Not for use in diagnostic procedures.
2. C lin ic a l r e le v a n c e
C-reactive Protein (CRP) is mainly formed in hepatocytes. The synthesis 
rate is determined by the influence of cytokines involved in inflammatory 
processes. The biological half-life is estimated to be 13-16 hours.
A connection between inflammatory reactions and cardiovascular diseases 
such as arteriosclerosis and latent or chronically persisting infections has 
been described in recent studies. The CRP concentrations of healthy 
persons are under 5 pg/ml. CRP belongs to the acute phase proteins and 
will be released within 24 hours after inflammatory process started (fever, 
pneumonia, myocardial infarction, etc.). CRP proved itself as a marker for 
inflammation.
Indications
• Risk factor for myocardial infarction or stroke
• Prognosis factor for infarct patients
• Inflammatory reactions
3, Principle of the test
This Enzyme Immunoassay is a sandwich assay for the determination of 
CRP in serum, plasma, urine and stool samples. The wells of the 
microtiter plate are coated with polyclonal antibodies directed against C- 
reactive Protein. In a first incubation step, the CRP in the samples is 
bound to the coated polyclonal rabbit antibodies (in excess). To remove 
all unbound substances, a washing step is carried out.
In a second incubation step, a Peroxidase-labeled CRP (PO-Antibody, 
polyclonal, rabbit-anti-CRP) antibody is added. After another washing 
step, to remove all unbound substances, the solid phase is incubated with 
the substrate, Tetramethylbenzidine (TMB). An acidic stopping solution is 
then added. The color converts to yellow. The intensity of the yellow color 
is directly proportional to the concentration of CRP in the sample. A dose
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response curve of the absorbance (at 450 nm) unit vs, concentration is 
generated. CRP, present in the patient samples, is determined directly 
from this calibration curve.
The combination of two specific antibodies in the CRP ELISA drastically 
reduces the possibility of false-negatives results and offers a secure 
diagnostic system to the user.
4. M a ter ia l su ppl ie d
The reagents of one kit are sufficient for 96 determinations.
Each test kit contains:
Catalog No. Kit Components Quantity
K9710SMTP one holder with precoated strips 96
K9710SWP ELISA wash buffer concentrate 10x 1 x 100 ml
K 9710sK POD antibody, (rabbit-anti-CRP, 
Peroxidase-labeled), prediluted
1 x 150 pi
K9710sST Calibrators, ready to use 
(0; 1.9; 5.6; 16.7; 50; 150 ng/m I)
6 x  1 ml
K 971OsKO Control, ready-to-use 1 x 1 ml
K9710SVP Dilution buffer, ready to use 2 x 1 0 0  ml
K971QSTMB TMB substrate (T etramethy Ibenzidine), 
ready to use
1 x 1 5  ml
K9710SAC ELISA stop solution, ready to use 1 x 7 ml
The CRP calibrators were standardized against WHO standard 470.
3
104
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5. Material  req uired  b u t  no t  s u p p l ie d
• Distilled or deionized water
• Laboratory Balance
• Sealing film to cover microtiter plate
• Horizontal microtiter plate shaker
• Precision pipettes calibrated to deliver 10-1000 pi and disposable tips
• A multi-channel dispenser or repeating dispenser
• Centrifuge capable of 3000 x g
• Absorbent paper
« Vortex-Mixer
• Microplate reader 450 nm
6.PREPARATION AND STORAGE OF REAGENTS
• To run the assay more than one time, make sure that the reagents 
are carefully stored at 2-8°C. Prepare just the appropriate amount 
necessary for the assay.
• Reagents with a volume of less than 100uL shold be centrifuged 
before use to avoid loss of volume.
s ^The ELISA wash buffer concentrate should be diluted with distilled 
' water 1:10 before use (add 450 ml distilled water to 50 ml ELISA wash 
buffer concentrate). Crystals may be formed due to high salt 
concentration. The crystals have to be dissolved before dilution of the 
buffer concentrate using a water bath (37°C). The buffer concentrates 
are stable at 2-8°C up to the expiry date stated on the label. Diluted 
solutions could be stored at 2-8°C for 1 month.
• Jfte POD labeled antibody has to be diluted 1:100 in ELISA wash
^buffer (100 pi POD antibody and 10 ml ELISA wash buffer). The
antibody is stable at 2 -4 °C up to the expiry date stated the label. 
Diluted antibody solution is not stable and can not be stored.
4
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7. P r e c a u tio n s
• For research use only. Not for use in diagnostic procedures.
• The calibrators and controls contain human source material which 
was tested and found to be non-reactive to HBsAg, anti-HiV-1/2. 
Since no method can offer complete assurance that hepatitis B virus, 
HIV-1/2, HCV or other infectious agents are absent, these reagents 
should be handled as if potentially infectious.
• The stop solution consists of diluted sulfuric acid, a strong acid. 
Although diluted, it still must be handled with care, it can cause burns 
and should be handled with gloves, eye protection, and appropriate 
protective clothing. Any spill should be wiped up immediately with 
copious quantities of water. Do not breathe vapor and avoid 
inhalation.
• Reagents should not be used beyond the expiration date stated on 
kit label.
8. SPEC1M EN COLLECT! ON AND PREPARATION 
Serum, plasma
Collection and storage of serum: Collect sufficient blood (at least 1 mi) by 
venipuncture into a tube or a plastic syringe, avoid hemolysis, centrifuge 
for 15 minutes a t 1,000 x g and 4<>C and collect the serum.
Collection and storage of plasma: Collect sufficient blood (at least 1 ml) by 
venipuncture into an EDTA venipuncture tube or a plastic syringe, 
centrifuge for 15 minutes at 1,000 x g and 4“C within 10 minutes after 
blood collection and separate the plasma from the cells.
Serum  and plasm a sam ples have to be diluted 1:100 or 1:500 before 
performing the assay.
Add 10 pi serum /plasma to 990 pi dilution buffer, mix well. (1:100)
Use the dilution factor (100 or 500) to calculate the CRP concentration read 
off the calibration curve.
Patient’s samples with elevated CRP concentrations must be diluted 
1:40Q0 -  1:8000. Samples of other patient collectives must be diluted 
according to the expected CRP concentration. The corresponding dilution 
factor must be used for calculation of the CRP concentration.
5
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Feces
The test can be performed on either fresh or frozen stooi samples. The 
samples should be refrigerated and can be stored at 2-8°C for 2 days. !f 
the test cannot be performed within this period the specimen should be 
stored at -20°C  or colder.
Add a stool sample of about 100 mg (size of a pea, please note the exact 
weight for the calculation) to 5 ml of the ELISA wash buffer and 
homogenize very thoroughly for 15 seconds on a Vortex-mixer. Centrifuge 
the suspension for 10 min at 3000 rpm. 1 ml of the supernatant is put into 
an Eppendorf tube and centrifuged once more at 13,000 rpm for 2 min. 
This supernatant can be stored at -2Q°C for about 1 month. 100 pi of 
this supernatant is used in the assay.
ALPCO recommends the use of Roche Diagnostics / Mannheim 
sample preparation tubes, article No. 745804, for sample preparation.
Urine
Urine samples have to be diluted 1:5 with dilution buffer.
9. A ssa y  procedure
Procedural notes
•  Do not mix different lot numbers of any kit component within the same 
assay.
• The quality control guidelines should be observed.
• Incubation time, incubation temperature and pipetting volumes of the 
different components are defined by the producer. Any variations of 
the test procedure, that are not coordinated with the producer, may 
influence the test results.
• Carry out the assay with the actual manual delivered with the kit.
6
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Test procedure
The precoated microtiter strips have to be washed 5 x with 250 pi ELISA 
wash buffer before use. Bring all reagents to room temperature. Mix 
reagents well before use. Avoid direct sun light during all incubation steps. 
Covering the microtitre plate during the different incubation steps is 
recommended. Carrying out the tests in duplicate is also recommended.
1. Add 100 pi of calibrator, controls or samples (in duplicate) into 
their respective wells, eg: 0 calibrator into A1 and A2, 1.9 
calibrator B1 and B2 and so on for each calibrator, then control 
into G1 and G2 and samples into the remain wells starting with 
H1 and H2, then A3 and A4, B3 and B4, and so on.
2. Incubate for 1 hour, shaking on a horizontal mixer, at room 
temperature.
3. Aspirate and wash the wells 5 x with 250 pi ELISA wash buffer.
4. Add 100 pi pre-diluted Peroxidase-labeled CRP antibody.
5. Incubate for 1 hour, shaking on a horizontal mixer, at room 
temperature.
6. Decant the content of the plate and wash the wells 5 x with 250pl 
ELISA wash buffer.
7. Add 100 pi TMB substrate solution into each well.
8. incubate for 5 -1 0  m inutes at room temperature in the dark.
9. Add 50 pi stop solution into each well and mix shortly.
10.Measure the extinction of the samples at 450 nm directly after 
adding the stop solution.
7
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10. R e s u l t s
A calibration curve is constructed from the standards. Commercially 
available software can be used as well as graph paper. Results of the 
samples are read from this calibration curve.
THE CALIBRATION CURVE IS NOT LINEAR, therefore a spline- or 4PL 
algorhythm is recommended.
Typical calibration curve
| |  BiOGRAPK Windows Application -  STANDARD CURVE
Ete £ #  Si!*" Wktliw £bom
W1" " "
IB S  la
CAP
:  i
i i l
. . . . . . . . . .
• M l
; n i l  
h i m :!;
J-LiiiUfc
| i
1
; !*i-?•
0.01 O’ 1 10 rng/mlj
^Parametsfs y - (erd)/(l ♦■|y/c),1b) <• d
8*0.03359 b - l i3 l  c*2i.22 <
R - 0 .3 9 S 8  B M 1 9 3 9 8  e r r - 0 .0 0 3 2 9 8
• NUkt
{Concentration [ng/ml] 150 50 16.7 5.6 1.9 0
jOD mean value 1.901 1.813 1.258 0.622 0.256 0.045
These data are for demonstration only and cannot be used instead of data 
obtained from the actual assay.
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Fecal
To calculate the CRP concentration of fecal specimen see  the 
following example:
weight:
dilution step 1: 
dilution factor:
80 mg (1ml stool = 1g) = 0.08 ml
5 m l/0.08 ml = 62.5
62.5
Multiply the results with the calculated dilution factor (in this case 62.5) to get 
the CRP concentration of the stool samples. Please note: the dilution factor 
depends on the weight of the used fecal specimen.
Serum, plasma
The value read of the calibration curve has to be multiplied by 100 or 500 
repectively to get the CRP concentration in serum/plasma samples.
If samples were diluted 1:4000 or 1:8000, the estimated values must be 
multiplied by 4000 or 8000 respectively.
Urine
The measured CRP concentration has to be multiplied by a factor of 5 to get 
the actual concentration of the samples.
11. Limitations
Samples with CRP levels greater than the highest calibrator, should be 
diluted and re-assayed.
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12. Q u a li t y  c o n t r o l
ALPCO recommends commercial control samples for internal quality 
control.
Control samples or serum pools should be analyzed with each run of 
calibrators and patient samples. Results, generated from the analysis of 
control samples, should be evaluated for acceptability using appropriate 
statistical methods. The results for the patient samples may not be valid, if 
within the sam e assay one or more values of the quality control sample are 
outside the acceptable limits.
Expected values 
Preliminary normal ranges:
Stool specimen <1.12 ng/ml
Urine samples <6 ng/ml
Serum/plasma:
Adults/children <0.068 -  8.2 mg/1
New borns/umbiiical cord <0.6 mg/l
Infants 4th day up to 1 month <1.6 mg/l
Pregnant women, at date of delivery <47 mg/l
(According to L. Thomas; Labor und Diagnose)
These normal ranges should be used as a guideline only. It is 
recommended that each laboratory establishes an own expected range for 
its patient population.
13 . P erfo rm a nce  characteristics 
Precision and reproducibility
The precision (intra-assay variation) of the CRP ELISA test was calculated 
from 20 replicate determinations on each one of the samples.
Intra-Assay CV n= 20
io
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Sample CRP 
Mean value 
[ng/ml]
Intra-Assay CV 
[%1
1 23.3 6
2 99.4 5.5
The total precision (inter-assay variation) of the CRP 
ELISA test was calculated from data on 2 samples obtained in 15 different 
assays by three technicians on two different lots of reagents over a period of 
three months.
Inter-Assay CV n= 15
Sample CRP Intra-Assay
Mean value 
[ng/ml]
CV[%]
1 22.1 11.6
2 90.4 13.8
11
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Sensitivity
n=20
CRP Mean Standard Detection
Sample value variation limit
[OD] [ng/ml]
1 0.053 0.007 0.124
Cross reactivity
Alpha-1-Antitrypsin 0%
Lysozym 0 %
Albumin 0 %
Other acute phase proteins 0 %
14. References
1. Koenig W et al. (2004) Circulation 109:1349-1353
2. Pearson TA et al. (2003) Circulation 107:645-651
3. Ridker P et al. (2000) N Eng J Med 342: 836-843
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15. G e n e r a l n o te s  on  th e  t e s t  and t e s t  p r o c e d u r e
• This assay was produced and put on the market according to the 
IVD guidelines of 98/79/EC.
• The test components which are made of human serum are tested 
for HVB and HIV and found to be negative. However, since no test 
method can offer complete assurance that infectious agents are 
absent, these reagents should be handled as recommended for 
any potentially infectious human serum or blood specimen. The 
normal precautions for laboratory working should be observed.
• Reagents of the test package contain sodium azide as a 
bactericide. Contact with skin or mucous membranes has to be 
avoided.
• All reagents in the test package are to be used for research use 
only. Not for use in diagnostic procedures.
• The reagents should not be used after the date of expiry (see 
label on the test package).
• Single components with different lot numbers should not be mixed 
or exchanged.
• The guidelines for medical laboratories should be observed.
• Incubation time, incubation temperature and pipetting volumes of 
the different components have been defined by the producer. Any 
alterations of the test procedure, that are not coordinated with the 
producer, may influence the results of the test.
I3
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K 971 Os Q u a l it y  C o n t r o l  P r o t o c o l
C -r e a c t iv e  P r o t e in  (C R P)
Lot: K9710S-070329
Kontrolle Ch. -  B7 Control lot; 0611 - 019 17.8ng/ml ( 1 4 .5 -27 .8  ng/m l)
yfcb  eft gew §#afs(t SSI#*# fibout
bWafl jlL'JxI Mj
CRPEUSA
1.4
1.2
1
08
OS
a 4
0 1 13 1000
nflAnl
4 y » *tx/cn>) + d
s-tLOltW b-J.1'/0 c-28.25 *1.631 
R *<13333 RMJ39# <j<e0.a0?652
■ v.. /  .■ ■ ■ .;T*~sa»r;" i
Standard-Cb. -  8./ calibrator lot; 0611 - 018
mean OD CV{%)
0.629 0.615 0,622
0.086 0,086
For Production:
For quality assurance: •"29/03/2007
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■ k  im m unoassay  Krfcs 
| |B  Beyond Tfre Ordinary
. » i
ProduktSpezifikation
CRP Kontrolle /  CRP control
Artikelnr./ Catalog no.: K9710sKO
Matrix: Phosphatpuffer /  Phosphatebuffer
Sicherheitshlnweis / 
Safety advice: EnthSIt <0,1% Thim erosaf/contains <0,1%Thimerosa!
Inhalt / Content: t ml
Bereich / range: 14 .5 - 27.8 ng/ml
D e ra n g e g e b e n e  Kontolfbereich ist m ir d e n  R eagenzien d es  TestMt CRP ELISA 
Artikelnr. K9710S e rm itte lt w o iden .
Der Einsatz a n d e re r M essystem e ew er R eagenxien kann zu  ab w eieh en d en  C rgebnissen 
fiihfen.
The g iven  range  w as m easu red  w ith reag en ts  of th e  CRP ELISA fcs't cata iogno . K9710 s.
The use o f o th e r  reag en ts  o r  system s o f m easu rem en ts  could g ive dev ia te  resuits.
Lagerung / Store at: 2 - 8 CC .
Ot.-8,/Lot: 0611 -0 1 9
Verwendbarbis/ 
Expiry date: 24.11.08
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Appendix I.
Data
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Data Appendices
subject group agepre htpre hiprem wtpre wtpost
1 15 C 34,20 168.00 1.68 97.00 97.10
2 19 c 24.00 162 00 1.62 66.50 65.70
3 33 c 48.30 169.00 1.69 56.40 55.20
4 34 c 47.90 174,00 1.74 71,20 69.60
5 35 c 35.70 168.00 1.68 58.20 58.80
6 37 c 21.50 155,00 1.55 60.40 56.80
7 i38 c 45.90 156.00 1.56 62.20 63.30
8 40 c 22.1CJ 162.50 1.63 67.80 69.80
9 41 c 45,20 160.00 1.60 58.70 60.30
10 42 c 47.70 170.50 i f  1 71.40 70.70
11 43 c 32.80 177.00 1.70 67.50 67.00
12 1 T 33.00 166.00 1.66 66.30 62.40
13 2 T 24.00 157.00 1.57 53.10 53.00
14 3 T 19.00 160.00 1.60 66.20 67.40
15 4 T 23.00 170.00 1.70 64.50 64.80
16 5 t 25.00 164.00 1.64 67.10 67.40
17 10 T 33.00 166.50 1-67j 106.00 107.60
18 11 T 33.00 162.50 1.63 56,50 Ot.So
19 13 T 26.00 167.30 1.67 70.30 73.00
20 14 T 23.00 164.00 1.64 57.20 57.50
21 16 T 22.00 177.00 1.77 112.70 110.50
22 17 T 39.00 170.00 1.70 103.10 105.10
23 21 T 27.66 164.50 1.65 69.60 67.40
24 22 T 47.10 169.50 1.70 98.60 97.50
25 23 T 47.30 170.50 1.71 66.90 66.80
26 24 T 46.50 166.00 1.66 57.10 57.20
27 27 T 45.20 159.50 1,60 51.10 51.10
28 29 T 46.10 165.40 1.65 84.40 80.30
29 30 T 21.00 168,00 1.88 59.70 58.60
30 31 T 39.40 157.50 1.58 54.30 53.90
31 32 T 44.40 176.50 1.77 77.90 77.00
32 36 T 33.30 167.50 1.68 117.40 117.90
6/22/2007 2:19:12 PM 1/20
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bmipre bmipost bsapre bsapost hrpre hrpost pppre
1 34.30 34.60 2.06 2.06 73.60 62.30 53.00
2 25.30 25.30 1.71 1.69 61,65 59.60 47.30
3 19.70 19.80 1.64 1,61 49.60 48.30 48.30
4 23.50 221.70 1.85 1.82 70.30 72.00 48.30
5 20.00 20.80 1.66 1.67 74.30 76.00 50.60
6 25.10 23.60 1.59 1.55 49.00 47.60 50.60
7 25.60 26.00 1.62 4.63 64.90 62.30 42.00
8 25.70 25.80 1.73 1.76 49.30 47.00 47.30
9 22.90 23.66 1.61 1.63 71.30 70.30 48.00
10 24.60 24.50 1.83 1.82 55.30 53.30 51.60
11 21.50 21,40 1.78 1.78 60.00 50.00 43.60
12 24.06 22.90 1.74 1.69 67.60 39.00 60.60
13 21.50 21.50 1.52 1.52 52.60 44.60 48.30
14 25.80 26.30 1.69 1.7Q 66.30 65.00 54.60
15 22.30 & .20 1.75 1.78 73.60 67.00 43.60
16 24.90 25.10 1.73 1.74 61.00 62.00 51.30
17 38.20 38.60 2.13 2.14 63.00 62,30l 43.00
18 21.30 21.90 1.60 1.61 54.30 61.60 46.60
19 25.10 26.10 1.79 1.82 55.60! 56.00 57.00
20 21.30 21.40 1.62 162 69.30 74.00 46.60
21 35.90 35.30 2.28 2.26 56.60 69.30 50.00
22 35.60 36.40 2.13 2.15 82.60 81.00 53.00
23 25> 0 24.60 1.76 1.75 84.00 62.00 50.60
24 34.30 33.50 2.09 2.09 68.00 64.30 49.00
25 23.00 22.70 1.78 1.79 68.60 74.30 58 60
26 20.70 21.30 1.63 1.62 77.30 72.30 46 30
27 20.10 20.10 1.51 1.51 71.60 68-00 43.00
28 30.90 29.90 1.92 1.87 59.60 58.30 53.30
29 21.20 20.80 1.68 1.66 62.30 58.30 44.60
30 21.90 22.30 1.54 1.52 75.80 83.30 39.60
31 25.00 24.70 1.95 1.94 64.00 64.60 48.30
32 41.80 41.66 2.23 2.24 60.30 82.60 59.00
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pppost sbppre dbppre sbppost dbppost hyptpre hyptpost
1 51.00 130.60 77.60 123.00 72.00 1.00 .00
2 47.00 124.60 77.30 112.00 65.00 .00 .00
3 46.00 109.00 60.60 111.60 65.60 .00 .00
4 47.00 123.30 75.00 116.60 69.60 .00 .00
5 47.30 119.30 68.80 111.00 63.60 .00 .00
6 46.60 113.30 62.60 110.30 63.60 .00 .00
7 43.30 103.30 61,30 107.60 64.30 .00 .00
8l 43.00 114.00 66.60 106.30 63.30 .00 .00
9 45.60 137.00 89.00 130.60 85.00 1.00 1.00
10 50.00 113.30 61.60 108.60 58.60 .00 .00
11 41.00 109.30 65.60 112.30 71.30 .00 .00
12 42.60 111.00 50.30 93.00 50.30 .00 .00
13 42.00 117.00 68.60 99.30 57.30 .00 .00
14 53,00 123.30 68.60 118.30 65.30 .00 .00
15 48.00 106.00 62.30 107.30 59.30 .00 .00
16 52.50 108.00 56.60 110.00 57.50 .00 .00
17 43.30 116.30 73.30 117.00 73.60 .00 .00
18 44.60 106.30 59.60 100.60 56.00 .00 .00
19 58.60 113.60 56.60 113.00 54.30 .00 .00
20 49.00 115.30 68,60 116.60 67.60 .00 .00
21 52.60 117.30 67.30 118.30 65.60 .00 .00
22 65.00 131.60 78.60 156.60 91.60 1.00 1.00
23 43.60 132.30 81.60 115.60 72.00 1.00 .00
24 54,60 117.60 68.60 132.60 78.00 .00 1.00
25 51.60 144.60 86.00 128.30 76.60 1.00 .00
26 43.30 118.30 72.00 111.00 67.60 .00 .00
27 46.00 103.60 60.60 106.00 60.00 .00 .00
28 57.00 128,30 75.00 127.00 70.00 .00 .00
29 41.60 108.60 64.00 104.00 62.30 .00 .00
30 52.00 117.60 78.00 129.60 77.60 .00 .00
31 49.00 119.30 71.00 119.60 70.60 .00 .00
32 50.60 141.00 82.00 117.60 67.00 1.00 .00
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bmdpre bmdpost tissgpre tissgpos fatgpre fatgpost leangpre
1 1.20 1.21 92944.00 93131.00 47313.00 47344.00 45632.00
2 1.16 1.17 63072.00 62112.00 27611.00 27400.00 35461.00
3 1.22 1.19 54137.00 52395.00 11741.00 11032.00 42396.00
4 1.12 1.12 67489.00 66039.00 30463.00 29682.00 37027.00
5 1.29 1.28 54329.00 55684.00 15710.00 17322.00 38619.00
6 1.14 1.14 57437.00 54228.00 18330.00 15420.00 39107.00
7 1.09 1.09 58617.00 60295.00 26271.00 26813.00 32346.00
8 1.17 1.15 64976.00 66160.00 27090.00 28298.00 37886.00
9 1.20 1.20 55489.00 57082.00 20064.00 20539,00 35424.00
10 1.21 1.20 67929.00 66835.00 26918.00 27065.00 41011.00
11 1.16 1.15 64888.00 64712.00 19663.00 18970.00 45225.00
12 1.23 1.22 62584.00 58755.00 27479.00 24734.00 35105.00
13 1.15 1.18 50454.00 50248.00 15039.00 14773.00 35415.00
14 1.24 1.21 63118.00 63900.00 21974.00 24154.00 41144.00
15 1.24 1.23 60901.00 61303.00 20497.00 19982.00 40404.00
16 1.25 1.24 64031.00 64080.00 22560.00 23696.00 41471.00
17 1,31 1.31 101914.0 103748.0 52655.00 53617.00 49258.00
18 1.12 1.13 53682.00 54684.00 17460.00 18025.00 36222.00
19 1.15 1.16 66920.00 69448.00 29452.00 31912.00 37468.00
20 1.19 1.17 54286,00 54443.00 18019.00 18430.00 36267.00
21 1.38 1.36 108551.0 106342.0 44632.00 46487.00 63919.00
22 1.26 1.33 99358.00 101629.0 47453.00 46200.00 51905.00
23 1.17 1.17 65804.00 64269.00 26174.00 21318.00 39630.00
24 1.33 1,34 95573.00 93715.00 47263.00 45475.00 48310.00
25 1.27 1.27 63544.00 63430.00 16388.00 15422.00 47156.00
26 1.15 1.15 53700.00 54053.00 18573.00 18939.00 35127,00
27 1.14 1.14 48283.00 48555.00 12226.00 13308.00 36057.00
28 1.30 1.30 80007.00 76089.00 37996.00 34408.00 42011.00
29 1.10 1.08 56968.00 56049.00 16055.00 14678.00 40914.00
30 1.20 1.21 51122.00 50911.00 17704.00 17378.00 33418.00
31 1.18 1.20 74413.00 73835.00 23938.00 20808.00 50475.00
32 1.25 1.28 113249.0 114145.0 58561.00 57080.00 54688.00
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leangpos bmcpre bmcpost Igfatpre Igfatpos Igtispre Igtispos
1 45787.00 2889.00 2905.00 52.60 51.30 36695.00 33513.00
2 34713.00 2520.00 2608.00 46.50 45.60 23392.00 22914.00
3 41363.00 2568.00 2514.00 23.30 21.40 19213.00 17852.00
4 36357.00 2571.00 2574.00 50.60 50.20 26560.00 25786.00
5 38361.00 2781.00 2854.00 35.10 36.00 19521.00 20193.00
6 38808.00 2160.00 2225.00 34.00 30.80 19662.00 18212.00
7 33482.00 2297.00 2201.00 51.10 52.50 23238.00 23785.00
8 37862.00 2790.00 2814.00 40.70 42.10 22093.00 21726.00
9 36543.00 2583.00 2557.00 35.80 35.50 18896.00 19501.00
10 39770.00 2750.00 2756.00 40.70 40.20 22147.00 21259.00
11 45743.00 2788.00 2759.00 29.00 28.40 21777.00 21969.00
12 34021.00 2725,00 2754.00 44,30 42.00 23238.00 21300.00
13 35475.00 2287.00 2264.00 32.70 32.50 18821.00 19677.00
14 39745.00 2596.10 2720.60 39.10 40.60 23830.00 24006.00
15 41321.00 2799.00 2767.00 36.50 35.10 21597.00 22030.00
16 40384.00 2680.00 2725.00 41.20 43.60 23370.00 23852.00
17 50130.00 2567.00 2552.00 49.20 50.10 37913.00 38296.00
18 36659.00 2250.00 2282.00 36.70 36.80 19616.00 20043.00
19 37536.00 2570.00 2782,00 46.70 45.10 23444.00 25127.00
20 36013.00 2416.00 2482.00 36.70 37,90 19761.00 19775.00
21 59855.00 3125.00 3335.00 33.70 33.90 32189.00 29229.00
22 55429.00 2834.00 2658.00 46.00 43.50 32293.00 35343.00
23 42951.00 2903.00 2694.00 40.90 36.10 22529.00 23245.00
24 48240.00 3184.00 3037.00 48.20 48.10 34012.00 30427.00
25 48009.00 3123.00 3089.00 31.50 29.20 22610.00 22400.00
26 35114.00 2498.00 2440.00 42.00 43.30 19158.00 19954.00
27 35247.00 2122.00 2171.00 27.10 28.80 15326.00 15266.00
28 41681.00 3179.00 3104.00 43.00 43.10 27122.00 24880.00
29 41371.00 2256.00 2304.00 33.90 32.40 23255.00 23046.00
30 33533.00 2385.00 2317.00 35.90 35.70 17054.00 17438.00
31 53027.00 2861.00 2826.00 36.90 33.60 28694.00 28273.00
32 57064.00 2882.00 2565.00 49.60 48.40 41395.00 42020.00
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Igfatgpr Igfatgpo Iglengpr iglengpo Igbmcpre Igbmcpos bfpre
1 19903.00 17753.00 16792.00 15760.00 1177.00 1103.00 49.40
2 11317.00 10894.00 12074.00 12020.00 957.00 977.00 42.10
3 4698.00 4020.00 14515.00 13832.00 965,00 918.00 20.70
4 13950.00 13434.00 12609.00 12352.00 1008.00 996.00 43.50
5 7223.00 7652.00 12298.00 12541.00 1085.00 1091,00 27.50
6 6978.00 5875.00 12684.00 12338.00 858.00 863.00 30.80
7 12274.00 12910.00 10964.00 10875.00 803.00 814.00 43.10
8 9367.00 9544.00 12726.00 12183.00 933.00 926.00 40.00
9 7098.00 7251.00 11799.00 12249.00 940.00 939.00 34.60
10 9416.00 8935.00 12731.00 12324.00 981.00 979.00 38.10
11 6617.00 6546.00 15160.00 15423.00 1034.00 1043.00 29.10
12 10750.00 9366.00 12488.00 11934,00 1025.00 1003.00 42.10
13 6421.00 6655.00 12400.00 13022,00 800.00 811.00 28.50
14 9665.00 10101.00 14165.00 13905.00 892.60 891.70 33.40
15 8253.00 8099.00 13344.00 13932.00 1022.00 1015.00 32.20
16 10025.00 10815.00 13345.00 13037.00 946.00 964.00 33.80
17 19234.00 19758.00 18679.00 18538.00 1168.00 1135.00 50.40
18 7495.00 7681.00 12122.00 12363.00 832.00 837.00 31.20
19 11399.00 11777.00 12045.00 13350.00 952.00 987.00 42.40
20 7566 .0? 7838.00 12194.00 11937.00 872.00 888.00 31.80
21 11312.00 10386.00 20876,00 18843.00 1394.00 1389.00 40.00
22 15398.00 15858.00 16895.00 19484.00 1146.00 1140.00 46.40
23 9585.00 8721.00 12944.00 14524.00 917.00 901.00 38.10
24 17001.00 15228.00 17011.00 15199.00 1242.00 1214.00 47.90
25 7452.00 6824.00 15159.00 15576.00 1030.00 999.00 24.60
26 8432.00 9047.00 10726.00 10907.00 926.00 925.00 33.00
27 4364.00 4618.00 10962.00 10648.00 759.00 767.00 24.30
28 12109.00 11189.00 15013 CO 13690.00 1064.00 1059.00 45.70
29 8177.00 7747.00 15078.00 15299.00 893.00 899.00 27.10
30 6411.00 6512.00 10644.00 10927.00 807.00 795.00 33.10
31 10953.00 9849.00 17741.00 18424.00 1016.00 1038.00 31.00
32 21135.00 20909.00 20261.00 21111.00 1203.00 1184.00 50.40
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bfpost c ip re l c1pre2 c1pre3 clpreavg c lp o stl c1post2
1 49.30 13.40 14.00 13.60 13.67 16.50 15.00
2 42.30 17.50 13.60 16.40 15.83 18.50 18.90
3 20.10 15.60 13.80 18.30 15.90 17.40 15.60
4 43.30 16.90 12.20 14,40 14.50 9.80 13.90
5 29.601 14.10 12.70 12.90 13.23 12.70 14.80
6 27.30 17.30 15.10 17.10 16.50 23.00 24.10
7 42.90 20.20 17.40 17.20 18.27 15.40 16.30
8 41.00 20.20 26.40 23.90 23.50 26.50 28.00
9 34.40 14.50 12.00 12.00 12.83 17.40 14.50
10 38.90 14.80 12.60 13.30 13.57 20.10 13.30
11 28.10 17.60 18.30 20.00 18.63 22.40 28.50
12 40.20 22.00 10.80 14.60 15.80 25.40 25.20
13 28.10 20.40 20.30 11.90 17.53 26.60 23.20
14 36.30 13.40 13.70 14.00 13.70 14.20 18.40
16 31.20 15.00 18.40 19.90 17.77 16.20 15.10
16 35.50 15.20 12.50 18.10 15.27 13,60 11.90
17 50.40 23.00 17.50 20.60 20.37 27.20 14.00
18 31.60 25.20 22.60 25.30 24.37 24.10 26.60
19 44.20 14.90 13.70 14.60 14.40 19,40 18.60
20 32.40 17.20 15.50 16.60 16.43 13.201 19.80
21 42.40 20.50 19.20 20.60 20.10 25.10 21.50
22 44.30 12.20 13.80 13.90 13.30 8.90 11.60
23 31.80 14.50 12.10 10.30 12.30 23.10 21.30
24 47.00 16.60 14.20 14.90 15.23 15.10 14.10
25 23.20 10.40 12.40 13.10 11.97 20.40 17.40
26 33.50 13.50 10.90 14.50 12.97 12.70 12.30
27 26.20 14.50 12.60 12.60 13.23 13.60 18.00
28 43.40 16.70 11.70 15.90 14.77 13.40 14.50
29 25.20 19.00 18.10 18.70 18.60 16.80 16.60
30 32.60 13.20 16.00 12.90 14.03 9.60 8.60
31 27.10 16.00 19.20 18.10 17.77 18.40 17.30
32 48.90 14.40 16.10 11,70 14.07 11.20 16.10
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d p o s t3 c lpostav c2pre1 c2pre2 c2pre3 c2preavg c2post1
1 16.60 16.03 6.00 4.40 7.10 5.83 13.80
2 15.30 17.57 7.90 5.80 8.30 7.33 6.90
3 17.90 16.97 10.30 11.70 10.90 10.97 9.90
4 13.30 12.33 4.50 5.70 4.80 5.00 6.90
5 14.90 14.13 5.80 5.30 6.00 5.70 5.40
6 25.10 24.07 8.10 9.80 11.10 9.67 9.60
7 16.10 15.93 7,50 6.90 8.10 7.50 5.50
8 21.10 25.20 7.50 7.50 8.20 7.73 9.30
9 14.80 15.57 3.70 3.80 3.60 3.70 5.10
10 16.70 16.70 12.50 12.90 13.60 13.00 13.60
11 23.00 24.63 15.00 15.30 11.30 13.87 9.20
12 34.80 28.47 10.00 9.10 12.10 10.40 11.20
13 19.40 23.07 8,50 6.10 5.40 6.67 7.20
14 15.20 15.93 11.50 7.70 12.40 10.53 9.60
15 15.80 15.70 7.50 6.90 8.70 7.70 7.60
16 12.75 10.70 7.60 12.10 10.13 8.20
17 28.10 23.10 14.30 9.50 10.10 11.30 10.70
18 23.00 24.57 7.10 8.20 5.50 6.93 10.30
19 19.00 19.00 12.10 7.40 7.40 8.97 7.00
20 15.10 16.03 6.80 5.20 5.40 5.80 4.90
21 21.60 22.73 9.60 10.60 14.70 11.63 10.10
22 10.60 10.37 4.00 4.10 6.50 4.87 3.80
23 19.10 21.17 5.60 4.20 3.80 4.53 10.30
24 12.00 13.73 9.80 9.60 10.60 10.00 10.50
25 13.80 17.20 4.50 5.10 7,20 5.60 6.80
26 15.00 13.331 4.50 4.10 3.70 4.10 5.50
27 12.60 14.73 13.00 13.90 10.70 12.53 12.00
28 9.90 12.60 7.70 5.60 4.90 6.07 5.10
29 20.10 17.83 5.30 5.70 5.40 5.47 6.10
30 7.70 8.63 3.20 5.60 3.301 4.03 2.10
31 19.70 18.471 10.00 4.60 6.90l 7.17 12.10
32 13.00 13.43 7.70 5.80 6.60 6.70 5.10
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c2post2 c2post3 c2postav svrpre svrpost tvipre tvipost
1 12.30 12.80 12.97 1193.60 1152.30 126.00 118.00
2 6.60 8.30 7.27 1400.30 1280.60 127.60 117.60
3 11.80 9.90 10.53 1415,60 1503.30 149.00 145.60
4 4.30 4.80 5.33 1404.60 1261.30 121.00 136.60
5 5.40 6.30 5.70 1244.00 1135.30 126.00 117.50
6 9.40 8.90 9.30 1333.30 1318.60 151.00 114.00
7 8.10 8.10 7.23 1213.3(7 1246.001 106.60 121.00
8 9.10 9.20 9.20 1304.60 1240.00 110.00 110.00
9 4.40 3.70 4.40 1820.00 1609.30 139.00 116.00
10 14.40 15.10 14.37 1253.00 1131.30 153.30 131.60
11 8.50 8.10 8.60 1092.60 1253.60 103.30 98.30
12 11.70 12.00 11.63 897.00 884.60 229.00 129.00
13 8.60 8.00 7.93 1383.30 1307.30 145.30 125.30
14 9.20 9.50 9.43 1111.60 1156.30 133.00 127.30
16 7.40 8.30 7.77 1031.60 1038.30 92.30 118.00
16 6.70 7.45 2273.60 977.50 136.00 143.50
17 7.10 10.80 9.53 1099.00 1100.60 94.00 91.60
18 8.40 11.60 10.07 1179.30 991.60 95.30 85.00
19 7.60 5.50 6.70 1089.30 1005.00 141.30 104.30
20 5.60 4.80 5.10 1171.00 1174.30 108.00 107.00
21 11.90 9.90 10.63 975.30 839.60 107.00 80.00
22 4.40 4.70 4.30 1239.60 1421.60 116.60 149.30
23 12.30 10.00 10.87 1367.00 1140.60 124.00 93.60
24 8.00 6.70 8.40 1054,30 1343.30 111.60 123,30
25 6.30 9.40 7.50 1520.60 1262.30 156.60 101.30
26 4.20 5.20 4.97 1460.60 1312.00 127.00 129.60
27 11.20 16.30 13.17 1229.00 1277.30 127.30 132.30
28 4.80 4.40 4.77 1336.00 1202.30 143.00 168.00
29 5.60 6.70 6.13 1185.30 1148.30 104.60 121.00
30 2.90 2.70 2.57 1568.30 1829.60 121.00 176.60
31 9.80 8.60 10.17 1190.30 1171.00 112.00 104.30
32 6.00 4.20 6.10 1180.60 934.00 131.60 115.60
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cprpre crppost hfpre hepre abdpre addpre Ippre
1 7.70 9.89 59.66 90.91 51.14 59.66 136.36
2 .27 .os' 51.14 51.14 28.41 39.77 72.73
3 .42 .75 56.82 73.86 45.45 56.82 104.55
4 1.02 1.10 39.77 59.66 39.77 45.45 104.55
5 1.12 1.04 48.30 62.50 36.93 48.30 81.82
6 .07 .22 56.82 90.91 45.45 62.50 127.27
7 1.30 .88 48.30 79.55 39.77 51.14 109.09
8 .75 .45 62.50 85.23 48.30 59.66 113.64
9 .98 1.67 45.45 73.86 39.77 51.14 81.82
10 .65 .37 48.30 65.34 34.09I 51.141 81.82
11 .52 .10 51.14 62.50 34.09 51.14 100.00
12 1.02 4.70 39.77 56.82 45.45 45.45 81.82
13 .45 .56 39.77 56.82 28.41 34.09 81.82
14 .52 1.29 39.77 42.61 31.25 36.93 127.27
16 4.60 8.40 39.77 71.02 36.93 56.82 109.09
16 1.40 1.59 56.82 68.18 42.61 53.98 100.00
17 2.70 6.20 51.14 62.50 45.45 56.82 100.00
18 .18 1.42 51.14 65.34 39.77 42.61 100.00
19 4.78 3.14 48.30 73.86 39.77 51.14 100.00
20 .20 .80 59.66 65,34 39.77 51.14* 104.65
21 .62 1.56 59.66 85.23 48.30 62.50 136.36
22 3.48 3.49 45.45 107.95 39.77 56.82 100.00
23 1.18 .56 62.50 62.50 36.93 51.14 109.09
24 .71 1.49 45.45 65.34 36.93 48.30 90.91
25 .11 .07 53.98 65.34 39.77 51.14 118.18
26 .93 1.09 36.93 65.34 36.93 39.77 100.00
27 .37 .38 31.25 56.82 34.09 39.77 90.91
28 15.40 4.78 45.45 79.55 51.14 53.98 131.82
29 .56 .45 56.82 82.50 39.77 56.82 100.00
30 .68 .40 48.30 48.30 39.77 36.93 90.91
31 .98 .25 51.14 76.70 31.25 45.45 113.64
32 6.60 10.60 62.50 76.70 48.30 62,50 168.18
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shinpre caifpre hfmid hemid abdmid addmid Ipmid
1 18.18 70.45
2 21.82 40.91
3 20,45 50.00
4 20.45 45.45
6 19,32 34.09
6 25.00 54.55
7 18.18 34.09
8 20.45 50,00
9 11.36 31.82
10 13.64 43.18
11 27.27 54.55
12 12.50 40.91 48.30 62.50 36.93 48.30 100.00
13 9.09 45.45 65.34 68.18 48.30 48.30 118.18
14 18,18 36.36 68.18 48.30 45.45 62.50 154.55
15 11.36 47.73 65.34 88.07 45.45 59.66 122.73
16 13.64 40.91 62.50 68.18 45.45 56.82 136.36
17 15.91 54.55 62.50 73.86 51.14 68.18 118.18
18 17.05 50.00 62.50 79.55 45.45 56.82 118.18
19 11.36 38.64 59.66 82.39 48.30 56.82 109.09
20 17.05 56.82 79.55 79.55 51.14 53.98 172.73
21 27.27 72.73 79.55 125.00 68.18 90.91 163.64
22 18.18 59.09 62.50 102.27 39.77 68.18 109.09
23 18.18 59.09 93.75 79.55 51.14 71.02 131.82
24 15.91 50.00 56.82 68.18 39.77 51.14 131.82
25 27.27 59.09 90.91 96.59 53.98 65.34 145.45
26 18.18 59.09 48.30 76.70 45.45 51.14 104.55
27 14.77 31.82 56.82 65.34 45.45 51.14 90.91
28 20.45 56.82 71.02 79.55 56.82 62.50 127.27
29 15.91 45.45 76.70 88.07 51.14 68.18 131.82
30 22.73 38.64 65.34 48.30 42.61 53.98 113.64
31 27.27 54.55 68.18 99.43 48.30 59.66 131.82
32 25.00 86.36 71.02 96.69 53.98 62.50 186.36
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shinmid calfmid hfpost hepost abdpost addpost lppost
1 85.23 116.48 62.50 73.86 136.36
2 73.86 68.18 36.93 42.61 109.09
3 53.98 73.86 45.45 45.45 118.18
4 48.30 73.86 39.77 53.98 113.64
5 48.30 73.86 34.09 45.45 109.09
6 51.14 68.18 45.45 56.82 104.55
7 66.82 65,34 42.61 48.30 109.09
8 65.34 90.91 53.98 62.50 136.36
9 45.45 56.82 42.61 53.98 81.82
10 51.14 73.86 42.61 56.82 95,45
11 48.30 68.18 36.93 45.45 109.09
12 22.73 45.45 65.34 79.55 48.30 62.50 113.64
13 20.45 63.64 88.07 85.23 68.18 68.18 118.18
14 20.45 43.18 65.34 82.39 42.61 56.82 204.55
15 20.45 61.36 102.27 107.95 62.50 71.02 122.73
16 20.45 54,55 82.39 85.23 59.66 71.02 186.36
17 20.45 86.36 79.55 110.80 59.66 82.39 131.82
18 22.73 59.09 79.55 82.39 53.98 56.82 131.82
19 20.45 68.18 82.39 88.07 59.66 65.34 109.09
20 22.73 68.18 107.95 107.95 79.55 79.55 163.64
21 23.86 122.73 117.70 119.40 90.91 118.00 213.64
22 22.73 68.18 102.27 120.00 68.18 85.23 131.82
23 20.45 84.09 117.20 107.95 59.66 73.86 145.45
24 22.73 81.82 76.70 90.91 48.30 56.82 113.64
25 22.73 88.64 99.43 99.43 62.50 65.34 140.91
26 20.45 66.82 51.14 71.02 42.61 51.14 118.18
27! 19.321 54.55 65.34 76.70 45.45 48.30 95.45
28 23.86 81.82 85.23 90.91 56.82 59.66 131.82
29 27.27 77.27 79.55 85.23 51.14 62.50 163.64
30! 23.86 S l T F 85.23 85.23 63.98 62.50 127.27
31 23.86 81.82 79.55 116.48 62.50 85.23 140.91
32 27.27 100.00 82.39 107.95 68.18 68.18 231.82
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shinpost calfpost sessions loadlhf ioadlhe loadlhab load 1 had
1 22.73 104.55
2 22.73 56.82
3 23.64 68.18
4 21.59 59.09
6 22.73 38.64
6 18.18 59.09
7 18.18 40.91
8 22.73 68.18
9 11.36 45.45
10 19.32 38.64
11 20.45 63.64
12 28.41 65.91 34.00 5500.00 7999.90 5999.90 5999.90
13 22.73 72.73 26.00 4000.00 5818.10 2909.00 3272.70
14 27.27 61.36 30.00 3500.00 3818.10 2545.40 3181.80
15 29.86 100.00 28.00 4500.00 8181.80 4090.90 6545.40
16 22.73 72.73 26.00 5818.10 6909.00 4363.60 5454.50
17 29.55 104.55 30.00 6999.90 8500.00 5999.90 7999.90
18 26.14 72.73 30.00 6999.90 8999.90 5500.00 5999.90
19 20.45 95.45 29.00 6500.00 9999.90 5500.00 6999.90
20 25.00 90.91 32.00 7272.70 8181.80 5000.00 6363.60
21 36.36 145.45 31.00 6545.40 9818.10 5318.10 6954.50
22 27.27 90.91 30.00 3818.10 9545.40 3500.00 5090.90
23 22.73 104.55 32.00 6954.50 6954.50 4254.50 5727.20
24 25.00 95.45 34.00 7090.90 10636.30 5909.00 7681.80
25 25.00 100.00 35.00 8181.80 9818.10 6000.00 7636.30
26 21.59 65.91 33.00 4545.40 8181.80 4545.40 5000.00
27 20.46 65.91 30.00 2909.00 5818.10 3272.70 4000.00
28 22.73 86.36 32.00 4363.60 8000.00 5090.90 5454.50
29 32.95 86.36 33.00 7272.70 7727.20 5000.00 7272.70
30 22.73 72.73 31.00 5318.10 5318.10 4500.00 4090.90
31 26.14 86.36 34.00 7636.00 11454.40 4363.60 6545.20
32 27.27 122.73 28.00 6181.80 7636.30 4727.20 6181.80
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loadllp loadlsh loadlcal load2hf load2he load2hab Ioad2had
1
2
3
4
5
6
7
8
9
10
11
12 16800.00 2640.00 8639.90 8272.70 10818.10 6363.60 8272.70
13 12218.10 1396.30 6981.80 7363.60 7772.70 5318.10 5318.10
14 16800.00 2443.60 4887.20 9500.00 6500.00 5999.90 8500.00
15 18249.50 1936.60 8247.20 9818.10 13090.90 6545.40 8727.20
16 14836.30 2094.50 6283.60 5409.00 6045.40 3818.10 5090.90
17 20399.90 3359.90 11760.00 7727.20 9090.90 6363.60 8636.30
18 20399.90 3599.90 10560.00 6545.40 8000.00 4727.20 5818.10
19 20399.90 2399.90 8160.00 7272,70 10454.50 5909.00 7272.70
20 19636.30 3272.70 10909.00 12000.00 12000.00 7636.30 8181.80
21 23563.60 4712.70 12567.20 12000.00 19090.90 10363.60 13636.30
22 12981.80 2443.60 7941.80 9272.70 15272.70 6000.00 10363.60
23 18654.50 3141.80 10210.90 10800.00 9000.00 5727.20 8181.80
24 22690.90 3970.90 12480.00 7999.90 9500.00 5500.00 6999.90
25 26181.80 6283.60 13614.50 14772.70 15954.50 8863.60 10636.30
26 16363.60 3490.90 4909.00 5909.00 9545.40 5454.50 6363.60
27 13963.60 2269.00 4887.20 7272.70 8181.80 5454.50 6363.60
28 20072.70 3141.80 8727.20 10909.00 12000.00 8727.20 9272.70
29 18545.40 3054.60 8727.20 9545.40 10909.00 6363.60 8636.30
30 15709.00 3927.20 5890.90 9818.10 8727.20 6545.40 8181.80
31 26181.60 5236.00 12567.20 9499.60 13999.90 6499.90 7999.90
32 25309.00 3840.00 13265.40 6454.50 7363.20 4090.80 4636.30
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foad2lp !oad2sh load2cal tvolpre tvolpGSt totalvol percchan
1
2
3
4
5
6
7
8
9
10
11
12 25963.60 6109.00 12216.10 53579.60 78017.80 131597.4 45.61
13 19636.30 3534.50 9818.10 36596.00 58761.40 95357.40 60.57
14 32400.00 4320.00 9119.90 37176.10 76339.80 113515.9 105.35
15 27490.20 4581.80 14138.10 51751.40 84391.70 136143.1 63.07
16 18327.20 2749.00 7330.90 45759.60 48770.50 94530.10 6.58
17 21818.10 3927.20 16581.80 65019.50 74145.10 139164.6 14.04
18 18327.20 3490.90 9076.30 62059,50 55985.10 118044.6 -9.79
19 20727.20 3927.20 13090.90 59959.60 68654.20 128613.8 14.50
20 39272.70 5236.30 15709.00 60636.10 100036.1 160672.2 64.98
21 36654,50 5498.10 28276.30 69479.60 125519.7 194999.3 80.66
22 24872.70 5236.30 15709.00 45321.60 86727.00 132048.6 91.36
23 22581.80 3534.50 14530.90 55897.90 74356.20 18458.30 33.02
24 27600.00 4799.90 17279.90 70459.80 79679.60 150139.4 13.09
25 35454.50 5672.70 22123.60 77716.10 113477.9 191194.0 46.02
26 19636.30 3927.20 10909.00 47036.10 61745.00 108781.1 31.27
27 17454.50 3709.00 10472.70 37119.60 58908.80 96028.40 58.70
28 28800.00 5498.10 18850.90 54850.70 94057.90 148908.6 71.48
29 22681.80 4712.70 13352.70 57599.70 76101.50 133701.2 32.12
30 26181.80 5498.10 12043.60 44754.20 76996.00 121750.2 72.04
31 27599.90 5039.90 17279.90 73984.00 87919.00 161903.0 18.84
32 20945.40 3141.80 11520.00 67141.50 57152.00 124293.5 -14.88
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agerank hrabscha hrpercch ppabscha pppercha sbpabsch sbpperch
1 1.00 -11.30 -15.35 -2.00 -3.77 -7.60 -5.82
2 .00 -2.00 -3.25 -.30 -.63 -12.60 -10.11
3 1.00 -1.30 -2.62 -2.30 -4.76 2.60 2.39
4 1.00 1.70 2.42 -1.30 -2.69 -6.70 -5.43
5 1.00 1.70 2.29 -3,30 -6.52 -8.30 -6.96
6 .00 -1.40 -2.86 -4.00 -7.91 -3.00 -2.65
7 1.00 -2.60 -4.01 1.30 3.10 4.30 4.16
S .00 -2.30 -4.67 -4.30 -9.09 -7.70 -6.75
9 1.00 -1.00 -1.40 -2.40 -5.00 -6.40 -4.67
10 1.00 -2.00 -3.62 -1.60 -3.10 -4.70 -4.15
11 .00 -10.00 -16.67 -2.60 -5.96 3.00 2.74
12 .00 -28.60 -42.31 -18.00 -29.70 -18.00 -16.22
13 .00 -8.00 -15.21 -6.30 -13.04 -17.70 -15.13
14 .00 -1.30 -1.96 -1.60 -2.93 -5.00 -4.06
15 .00 -6.60 -8.97 4.40 10.09 1.30 1.23
16 .00 1.00 1.64 1.20 2.34 2.00 1.85
17 .00 -.70 -1.11 .30 .70 .70 .60
18 .00 7.30 13.44 -2.00 -4.29 -5.70 -5.36
19 .00 .40 .72 1.60 2.81 -.60 -.53
20 .00 4.70 6.78 2.40 5.15 1.30 1.13
21 .00 12.70 22.44 2.60 5.20 1.00 .85
22 1.00 -1.60 -1.94 12.00 22.64 25.00 19.00
23 33.02 -22.00 -26.19 -7.00 -13.83 -16.70 -12.62
24 1.00 -3.70 -5.44 5.60 11.43 15.00 12.76
25 1.00 5.70 8.31 -7.00 -11.95 -16.30 -11.27
26 1.00 -5.00 -6.47 -3.00 -6.48 -7.30 -6.17
27 1.00 -3.60 -5.03 3.00 6.98 2.40 2.32
28 1.00 -1.30 -2.18 3.70 6.94 -1.30 -1.01
29 .00 -4.00 -6.42 -3.00 -6.73 -4.60 -4.24
30 1.00 7.70 10.19 12.40 31.31 12.00 10.20
31 1.00 .60 .94 .70 1.45 .30 .25
32 .00 22,30 36.98 -8.40 -14.24 -23.40 -16.60
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dpbabsch dbpperch clabsoch d p e rch a c2absoch c2percha svrabsoc
1 -5.60 -7.22 2.37 17.32 7.13 122.29 -41.30
2 -12.30 -15.91 1.73 10.95 -.07 -.91 -119.70
3 5.00 8.25 1.07 6.71 -.43 -3.95 87.70
4 -5.40 -7.20 -2.17 -14.94 .33 6.67 -143.30
5 -5.20 -7.56 .90 6.80 .00 .00 -108.70
6 1.00 1.60 7.57 45.86 -.37 -3.79 -14.70
7 3.00 4.89 -2.33 -12.77 -.27 -3.56 32.70
8 -3.30 -4.95 1.70 7.23 1.47 18.97 -64.60
9 -4.00 -4.49 2.73 21.30 .70 18.92 -210.70
10 -3,00 -4.87 3.13 23.10 1.37 10.51 -121.70
11 5.70 8.69 6.00 32.20 -5.27 -37.98 161.00
12 .00 .00 12.67 80.17 1.23 11.86 -12.40
13 -11.30 -16.47 5.53 31.56 1.27 19.00 -76.00
14 -3.30 -4.81 2.23 16,30 -1.10 -10.44 44.70
16 -3.00 -4.82 -2.07 -11.63 .07 .87 6.70
16 .90 1.59 -2.52 -16.48 -2.68 -26.48 -1296.10
17 .30 .41 2.73 13.42 -1.77 -15.63 1.60
18 -3.60 -6.04 .20 .82 3.13 45.19 -187.70
19 -2.30 -4.06 4.60 31.94 -2.27 -25.28 -84.30
20 -1.00 -1.46 -.40 -2.43 -.70 -12.07 3.30
21 -1.70 -2.53 2.63 13.10 -1.00 -8.60 -135.70
22 13,00 16.54 -2.93 -22.06 -.57 -11.64 182.00
23 -9.60 -11.76 8.87 72.09 6.33 139.71 -226.40
24 9.40 13.70 -1.50 -9.85 -1.60 -16.00 289.00
25 -9.40 -10.93 5.23 43.73 1.90 33.93 -258.30
26 -4.40 -6.11 .37 2.83 .87 21.14 -148.60
27 -.60 -.99 1.50 11.34 .63 5.05 48.30
28 -5.00 -6.67 -2.17 -14.67 -1.30 -21.43 -133.70
28 -1.70 -2.66 -.77 -4.12 .67 12.20 -37.00
30 -.40 -.51 -5.40 -38.48 -1.47 -36.36 261.30
31 -.40 -.56 .70 3.94 3.00 41.86 -19.30
32 -15.00 -18.29 -.63 -4,50 -1.60 -23.88 -246,60
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svrperch tviabsch tviperch crpabsoc crpperch hfabscha hfpercch
1 -3.46 -8.00 -6.35 2.19 28.44 25.57 42.86
2 -8.55 -10.00 -7.84 -.21 -78.89 22.73 44.44
3 6.20 -3.40 -2.28 .33 78.57 -2.84 -5.00
4 -10.20 15.60 12.89 .08 7.84 8.52 21.43’
6 -8.74 -8.50 -6.75 -.08 -7.14 .00 .00
6 -1.10 -37.00 -24.50 .15 197.30 -5.68 -10.00
7 2.70 14.40 13.51 -.42 -32.31 8.52 17.65
8 -4.95 .00 .00 -.30 -40.00 2.84 4.55
9 -11.58 -23.00 -16.55 .69 70.41 .00 .00
10 -9.71 -21.70 -14.16 -.28 -43.08 2.84 5.88
11 14.74 -5.00 -4.84 -.42 -80.77 -2.84 -5.56
12 -1.38 -100.00 -43.67 3.68 360.78 25.57 64.29
13 -5.49 -20.00 -13.76 .11 24.44 48.30 121.43
14 4.02 -5.70 -4.29 .77 148.08 25.57 64.29
15 .65 25.70 27.84 3.80 32.61 62.50 157.14
16 -57.01 7.50 5.51 .19 13.57 25.57 45.00
17 .15 -2.40 -2.55 3.50 129.63 28.41 55.56
18 -15.92 -10.30 -10.81 1.24 688.89 28.41 55.56
19 -7.74 -37.00 -26.19 -1.64 -34.31 34.09 70.59
20 .28 -1.00 -.93 .60 300.00 48,30 80.95
21 -13.91 -27.00 -25.23 .94 151.61 58.04 97.29
22 14.68 32.70 28.04 .01 .29 56.82 125.00
23 -16.56 -30.40 -24.52 -.62 -52.54 54 70 87.52
24 27.41 11.70 10.48 .78 109.86 31.25 68.75
25 -16.99 -55.30 -35.31 -.04 -36.36 45.45 84,21
26 -10.17 2.60 2.05 .16 17.20 14.20 38.46
27 3.93 5.00 3,93 .01 2.70 34.09 109.09
28 -10.01 25.00 17.48 -10.62 -68.96 39.77 87.50
29 -3.12 16.40 15.68 -.11 -19.64 22.73 40.00
30 16.66 55.60 45.95 -.28 -41.18* 36.93 76.47
31 -1.62 -7.70 -6.88 -.73 -74.49 28.41 55.56
32 -20.89 -16.00 -12.16 4.00 60.61 19.89 31.82
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heabsch hepercch abdabsch abdperec addabsch addperch Ipabscha
1 25.57 28.13 11.36 22.22 14.20 23.81 .00
2 17.05 33.33 8.52 30.00 2.84 7.14 36.36
3 .00 .00 .00 .00 -11.36 -20.00 13.64
4 14.20 23.81 .00 .00 8,52 18.75 9.09
S 11.36 18.18 -2.84 -7.69 -2.84 -5.88 27.27
6 -22.73 -26.00 .00 .00 -5.68 -9,09 -22.73
7 -14.20 -17.86 2.84 7.14 -2.84 -5.56 .00
8 5.68 6.67 5.68 11.76 2.84 4.76 22.73
9 -17.05 -23.08 2.84 7.14 2.84 5.56 .00
10 8.52 13.04 8.52 25,00 5.68 11.11 13.64
11 5.68 9.09" 2.84 8.33 -5.68 -11.11 9.09
12 22.73 40.00 2.84 6.25 17.05 37.50 31.82
13 28.41 50.00 39.77 140.00 34.09 100.00 36.36
14 39.77 93.33 11.36 36.36 19.89 53.85 77.27
15 38.93 52.00 25.57 69.23 14.20 25.00 13.64
16 17.05 25.00 17.05 40.00 17.05 31.58 86.36
17 48.30 77.27 14.20 31.25 25,57 45.00 31.82
18 17.05 26.09 14.20 35.71 14.20 33.33 31.82
19 14.20 19.23 19.89 50.00 14.20 27.78 9.09
20 42.61 65.22 39.77 100.00 28.41 55.56 59.09
21 34.17 40.10 42.61 88.24 55.50 88.80 77.27
22 12.05 11.16 28.41 71.43 28.41 50.00 31.82
23 45.45 72.73 22.73 61.54 22.73 44.44 36.36
24 25.57 39.13 11.36 30.77 8.52 17.65 22.73
25 34.09 52.17 22.73 57.14 14.20 27.78 22.73
26 5.68 8.70 5.68 15.38 11.36 28.57 18.18
27 19.89 35.00 11.36 33.33 8.52 21.43 4.55
28 11.36 14.29 5.68 11.11 5.68 10.53 .00
29 22.73 36.36 11.36 28.57 5.68 10.00 63.64
30 36.93 76.47 14.20 35.71 25.57 69.23 36.36
31 39.77 51.85 31.25 100.00 39.77 87.50 27.27
32 31.25 40.74 19.89 41.18 5.68 9.09 63.64
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Igpercch shinabsc shinperc caifabsc caifperc
1 .00 4.55 25.00 34.09 48.39
2 50.00 .91 4.17 15.91 38.89
3 13.04 3.18 15.56 18.18 36.36
4 8.70 1.14 5.56 13.64 30.00
5 33.33 3.41 17.65 4.55 13.33
6 -17.86 -6.82 -27.27 4.55 8.33
7 .00 .00 .00 6.82 20.00
8 20.00 2.27 11.11 18.18 36.36
9 .00 .00 .00 13.64 42.86
10 16.67 5.68 41.67 -4.55 -10.53
11 9.09 -6.82 -25.00 9.09 16.67
12 38.89 15.91 127.27 25.00 61.11
13 44.44 13.64 150.00 27.27 60.00
14 60.71 9.09 50.00 25.00 68.75
15 12.50 18.50 162.80 52.27 109.52
16 86.36 9.09 66.67 31.82 77.78
17 31.82 13.64 85.71 50,00 91.67
18 31.82 9.09 53.331 22.73 45.45
19 9.09 9.09 80.00 56.82 147.06
20 56.52 7.95 46.67 34.09 60.00
21 56.67 9.09 33.33 72.73 100.00
22 31.82 9.09 50.00 31.82 53.85
23 33.33 4.55 25.00 45.45 76.92
24 25.00 9.09 57.14 45.45 90.91
25 19.23 -2.27 -8.33 40.91 69.23
26 18.18 3.41 18.75 6.82 11.54
27 5.00 5.68 38.46 34.09 107.14
28 .00 2.27 11.11 29.55 52.00
29 83.64 17.05 107.14 40.91 90.00
30 40.00 .00 .00 34.09 88.24
31 24.00 -1.14 -4.17 31.82 58.33
32 37.84 2.27 9.09 36.36 42.11
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General Linear Model
Within-Subjects Factors
M easure: MEASURE_1
Dependent
TRIALS Variable
1 C1PREAVG
2 C1POSTAV
Between-Subjects Factors
N
GROUP C 
T
11
21
Descriptive Statistics
GROUP M ean Std. Deviation N
C1PREAVG C 16.0394 3.16055 11
T 15.9032 3.11021 21
Total 15.9500 3.07693 32
C1POSTAV C 18.1030 4.43392 11
T 17.2786 5.07643 21
Total 17.5620 4.80895 32
Tests of Within-Subjects Effects
M easure: MEASURE_1
Source
Type III Sum 
of Squares df Mean Square F .... s i9
TRIALS Sphericity A ssum ed 42.688 1 42.688 5.761 .023
G reenhouse-G eisser 42.688 1.000 42.688 5.761 .023
Huynh-Feldt 42.688 1.000 42.688 5.761 .023
Lower-bound 42.688 1.000 42.688 5.761 .023
TRIALS * GROUP Sphericity A ssum ed 1.710 1 1.710 .231 .634
G reenhouse-G eisser 1.710 1.000 1.710 .231 .634
Huynh-Feldt 1.710 1.000 1.710 .231 .634
Lower-bound 1.710 1.000 1.710 .231 .634
Error(TRIALS) Sphericity A ssum ed 
G reenhouse-G eisser 
Huynh-Feldt 
Lower-bound
222.277
222.277
222.277
222.277
30
30.000
30.000
30.000
7.409
7.409
7.409
7.409
Tests of Between-Subjects Effects
M easure: M EA SU REJ 
Transformed Variable: A verage
Source
Type ill Sum 
of Squares df Mean Square F .... ____
Intercept 16359.651 1 16359.651 626.741 .000
GROUP 3.331 1 3.331 .128 .723
Error 783.082 30 26.103
P a g e  1
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General Linear Model
Within-Subjects Factors
Measure: MEASURE_1
D ependent
TRIALS Variable
1 C2PREAVG
2 C2POSTAV
Between-Subjects Factors
N
GROUP C 11
T 21
Descriptive Statistics
GROUP Mean Std. Deviation N
C2PREAVG C 8.2091 3.29781 11
T 7.6730 2.67382 21
Total 7.8573 2.86140 32
C2POSTAV C 8.6273 3.11879 11
T 7.8183 2.76909 21
Total 8.0964 2.87004 32
Tests of Within-Subjects Effects
Measure: MEASUREJ
Source
Type III Sum 
of Sduares df Mean Square F Sig.
TRIALS Sphericity A ssum ed 1.146 1 1.146 .391 .637
G reenhouse-G eisser 1.146 1.000 1.146 .391 .537
Huynh-Feldt 1.146 1.000 1.146 .391 .537
Lower-bound 1.146 1.000 1.146 .391 .537
TRIALS‘ GROUP Sphericity A ssum ed .269 1 .269 .092 .764
G reenhouse-G eisser .269 1.000 .269 .092 .764
Huynh-Feldt .269 1.000 .269 .092 .764
Lower-bound .269 1.000 .269 .092 .764
Error(TRIALS) Sphericity Assum ed 87.990 30 2.933
G reenhouse-G eisser 87.990 30.000 2.933
Huynh-Feldt 87.990 30.000 2.933
Lower-bound 87.990 30.000 2.933
Tests of Between-Subjects Effects
Measure: MEASUREJ 
Transformed Variable: Average
Source
Type III Sum 
of Squares df Mean Square F Sig.
Intercept 3772.071 1 3772.071 273.089 .000
GROUP 6.530 1 6.530 .473 .497
Error 414.378 30 13.813
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General Linear Model
Within-Subjects Factors 
Measure: MEASUREJ
D ependent
TRIALS Variable
1 CPRPRE
2 CRPPOST
Between-Subjects Factors
N
GROUP C 11
T 21
Descriptive Statistics
GROUP Mean Std. Deviation N
CPRPRE C 1.3458 2.14060 11
T 2.2605 3.50286 21
Total 1.9461 3.09663 32
CRPPOST C 1.5025 2.82488 11
T 2.5343 2.89271 21
Total 2.1796 2.86717 32
Tests of Within-Subjects Effects
Measure: MEASUREJ
Source
Type III Sum 
of Squares df Mean Square F Siq.
TRIALS Sphericity A ssum ed .669 1 .669 .222 .641
G reenhouse-G eisser .669 1.000 .669 .222 .641
Huynh-Feldt .669 1.000 .669 .222 .641
Lower-bound .669 1.000 .669 .222 .641
TRIALS * GROUP Sphericity A ssum ed .050 1 .050 .016 .899
G reenhouse-G eisser .050 1.000 .050 .016 .899
Huynh-Feldt .050 1.000 .050 .016 .899
Lower-bound .050 1.000 .050 .016 .899
Error(TRIALS) Sphericity A ssum ed 90.455 30 3.015
G reenhouse-G eisser 90.456 30.000 3.015
Huynh-Feldt 90.455 30.000 3.015
Lower-bound 90.455 30.000 3.015
Tests of Between-Subjects Effects
Measure: MEASUREJ 
Transformed Variable: Average
Source
Type III Sum 
of Squares df Mean Square F Sig.
Intercept 210.845 1 210.845 14.122 .001
GROUP 13.675 1 13.675 .916 .346
Error 447.923 30 14.931
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